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ABSTRACT
Chlamydia pneumoniae (C. pneumoniae) is a common human pathogen causing a 
range of respiratory diseases from pharyngitis to pneumonia. Even though the 
majority of diseases are mild or even asymptomatic, persistent C. pneumoniae
infections have been associated with chronic diseases such as asthma and 
atherosclerosis which represent significant health problems in many countries. 
Consequently, the development of a safe and effective vaccine is an attractive 
approach that would have a great impact on the prevalence of chlamydial 
infections and the prevention of severe consequences.  
Studies on the pathogenesis of C. pneumoniae infection and the host immune 
response to infection have been greatly aided by well-established mouse models. 
Intranasal C. pneumoniae challenge of mice leads to a self-restricted pulmonary 
infection, and a partially protective immunity in which IFN-γ and T lymphocytes, 
especially CD8+ T cells, play a predominant role. Research objectives of this 
thesis included characterization of mechanisms for the targeted induction of 
cytotoxic CD8+ T lymphocyte (CTL) response against C. pneumoniae infection in 
vivo. Using a computer-based method for predicting the binding of chlamydial 
peptides to major histocompatibility complex (MHC) class I molecules, candidate 
CD8 epitopes were identified from C. pneumoniae proteins, and used for peptide 
immunization of mice. Nineteen C. pneumoniae-derived peptides were identified 
as CD8 epitopes by their ability to induce cytotoxic response after peptide 
immunization. Seven of the identified epitopes were able to induce long-term 
peptide-specific CTL lines, and three were natural epitopes presented by C.
pneumoniae infected cells. Identification of CD8 epitopes served as a tool for the 
characterization of CD8+ T lymphocyte function after various anti-chlamydia 
immunization approaches. 
Similarly, human CD8 epitopes were identified in transgenic HHD mice 
expressing only human class I molecule (HLA-A2.1). Immunization of HHD 
mice with the whole chlamydial protein induced an HLA-A2.1-restricted peptide-
specific CTL line, indicating that the classical human class I molecule can support 
the development of murine CD8+ T cell response against a chlamydial protein. In 
spite of a lower number of CD8+ T cells in HHD mice, the outcome of C.
pneumoniae infection in the transgenic mice resembled that observed in the wild 
type mice. These findings encourage the use of HHD mouse model for the further 
characterization of C. pneumoniae infection and the host immunity against it, as 
well as for identification of human CD8 epitopes from chlamydial antigens. 
DNA-based vaccines coding for desired chlamydial protein are effective vehicles 
in delivering antigen into the eukaryotic cells and inducing both humoral and 
cellular antigen-specific immune response. However, DNA immunizations have 
induced only partial protection against C. pneumoniae infection. In an attempt to 
find a more potent immunization strategy, we cloned C. pneumoniae MOMP and 
Omp2 genes into the Semliki Forest virus vector and immunized mice with these 
recombinant viral particles (rSFV). rSFV vaccination, with or without DNA 
priming, induced antigen-specific humoral and cellular immune responses as well 
as partial protection against C. pneumoniae pulmonary infection. In addition, 
immunization with rSFV induced specific CTL responses against the very same 
chlamydial epitopes that were identified after DNA immunization, indicating that 
both antigen delivery systems can result in similar MHC class I-dependent antigen 
processing and presentation. Although the rSFV vaccination using chlamydial 
MOMP and Omp2 antigen is not sufficient alone to achieve complete protection, 
this immunization strategy mobilized a wide range of antigen-specific effector 
mechanisms and speaks in favor of genetic constructs for evaluating vaccine 
antigens against C. pneumoniae infection.
Chlamydial proteins that are secreted out of the inclusion or associated with the 
inclusion membrane are potential targets for the host’s MHC class I-dependent 
antigen presentation, thereby representing ideal antigens for CD8+ T cell-based 
vaccination. Chlamydiae interact actively with the host cell, presumably by 
exploiting a type three secretion system (TTSS). We demonstrated that a TTSS-
secreted chlamydial outer protein N (CopN) as a vaccine induced a strong 
humoral and cellular immune response, detected as antigen-specific antibodies, 
proliferation and IFN-γ production. Most importantly, the CopN immunization 
induced a significant level of protection against subsequent C. pneumoniae
infection which certainly recommends this antigen as a candidate vaccine for 
further investigation.  
Keywords: Chlamydia pneumoniae, mouse model, CD8+ T cell, CD8  
epitope, immunization  
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TIIVISTELMÄ 
Chlamydia pneumoniae eli keuhkoklamydia on pieni solunsisäinen bakteeri, joka 
aiheuttaa yleisesti hengitystieinfektioita. Keuhkoklamydian uusintainfektiot ovat 
tavallisia ja osa infektioista kroonistuu, jolloin kudosvaurioita syntyy sekä 
infektion että puolustusjärjestelmän toiminnan seurauksena. Krooninen 
keuhkoklamydiainfektio on yhdistetty moniin vakaviin sairauksiin, kuten sydän- 
ja verisuonitauteihin sekä astmaan. Mahdollinen yhteys kansanterveydellisesti 
merkittäviin tauteihin on vilkastuttanut klamydiatutkimusta ja suojaavan rokotteen 
kehittelytyötä. 
C. pneumoniae aiheuttaa hiirille lievän, itsestään rajoittuvan keuhkoinfektion. 
Kulultaan se muistuttaa ihmisen infektiota ja tarjoaa näin erinomaisen lähtökohdan 
infektiolta suojaavan immuunivasteen selvittämiselle. T solut, erityisesti CD8+ T 
lymfosyytit, sekä IFN-γ sytokiini ovat osoittautuneet tärkeiksi suojaavan 
immuunivasteen osatekijöiksi. Väitöskirjatyön tarkoituksena oli kehittää 
menetelmiä, joilla voidaan stimuloida klamydiaspesifistä soluvälitteistä 
immuniteettia ja erityisesti CD8+ T soluvastetta. Työssä identifioitiin 
klamydiaproteiineista epitooppeja, joita infektoitunut isäntäsolu pyrkii 
esittelemään MHC luokka I molekyylien välityksellä CD8+ T soluille. 
Identifioinnissa käytettiin hyväksi klamydiaproteiinien tunnettuja 
aminohapposekvenssejä sekä tietoa eri MHC I rakenteiden kyvystä sitoa 
peptidirakenteita. Immunisaation jälkeen 19 klamydiaperäistä peptidiä sai aikaan 
CD8+ T soluvasteen hiirissä, ja kolme peptideistä varmistettiin luonnollisiksi 
epitoopeiksi, joita keuhkoklamydian infektoimat solut esittelevät pinnallaan. 
Identifioituja epitooppeja hyödynnettiin selvitettäessä eri immunisaatiotapojen 
kykyä herättää CD8+ T soluvasteita. Käyttämällä ihmisen HLA-A2.1 
esittelijämolekyyliä ilmentäviä siirtogeenisiä HHD hiiriä, voitiin identifioida 
sellaisia klamydian epitooppeja, joita esitellään ihmisen HLA-järjestelmässä. 
HHD hiirten immunisaatiokokeet osoittivat, että ihmisen HLA-A2.1 
esittelijämolekyylit ja hiiren CD8+ T solut pystyivät toimimaan yhdessä. Tulosten 
perusteella HHD-hiirimallia voidaan hyödyntää CD8-epitooppien identifioinnissa 
ja keuhkoklamydian patogeneesin selvittelyssä. 
Työn aikana keuhkoklamydian geenejä kloonattiin Semliki Forest virusvektoriin 
(SFV) ja näillä virusvektoreilla (rSFV) immunisoitiin hiiriä. Vaikka 
keuhkoklamydian ulkomembraaniproteiineja (MOMP ja Omp2) koodittavilla 
rSFV partikkeleilla saatiin vain osittainen suoja infektiota vastaan, 
immunisaatiotavan havaittiin aktivoivan monia immuunipuolustuksen osatekijöitä. 
Menetelmää voidaankin hyödyntää testattaessa muita rokotekandidaatteja. Lisäksi 
havaittiin, että sekä rSFV immunisaation että aiemmin käyttämämme DNA 
immunisaation jälkeen voitiin eristää samoille klamydian epitoopeille spesifisiä 
CD8+ T solulinjoja. Kumpikin käytetty vektori ohjasi siis koodittamansa 
klamydiaproteiinit samalle prosessointireitille, joka tuotti samat peptidit 
esiteltäväksi CD8+T soluille.  
Klamydialla havaittu tyypin III eritysreitti (TTSS) tarjoaa solun sisällä 
lisääntyvälle, mutta inkluusiomembraanin ympäröimälle bakteerille 
mahdollisuuden olla vuorovaikutuksessa isäntäsolun kanssa. 
Inkluusiomembraanille tai isäntäsolun sytoplasmaan eritettävät bakteeriperäiset 
proteiinit ovat siten potentiaalisia T-solurokotteen antigeenejä. Työssä 
immunisoimme hiiriä lämpökäsitellyllä klamydian ulkomembraaniproteiinilla 
CopN, joka on TTSS:n kautta erittyvä proteiini. CopN immunisaatio sai hiirissä 
aikaan antigeenispesifisten vasta-aineiden tuoton, soluproliferaation sekä IFN-γ
tuoton. Lisäksi havaittiin, että CopN immunisaatio suojasi merkittävästi hiiriä 
immunisaatiota seuraavalta C. pneumoniae-infektiolta, mikä rohkaisee tutkimaan 
CopN antigeenia jatkossa rokotekandidaattina keuhkoklamydiainfektiota vastaan.  
Avainsanat: keuhkoklamydia, hiirimalli, CD8+ T solut, CD8 epitoopit, 
immunisaatio 
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ABBREVIATIONS 
APC antigen presenting cell 
bp base pair 
COMC chlamydial outer membrane complex 
CopN chlamydial outer protein N 
CPAF chlamydial proteasome-like activity factor  
CTL cytotoxic CD8+ T lymphocytes  
DC dendritic cell 
DNA deoxyribonucleic acid 
EB elementary body 
EIA enzyme immunoassay 
ER endoplasmic reticulum 
FITC fluorescein isothiocyanate 
GTPase guanosine triphosphatase 
HHD HLA-A2.1 transgenic mice 
HLA human leucocyte antigen 
Hsp60 heat shock protein 60 
IDO indoleamine-2,3-dioxygenase 
IFU inclusion forming unit 
Ig immunoglobulin 
IL interleukin 
Inc inclusion membrane protein  
IFN interferon 
kDa kilodalton  
LPS lipopolysaccharide 
LT Escherichia coli heat-labile toxin 
MHC  major histocompatibility complex 
mLN mediastinal lymph nodes 
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MOMP major outer membrane protein 
MoPn Chlamydia trachomatis mouse pneumonitis 
NK natural killer  
Omp2 outer membrane protein 2 
OVA ovalbumin 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI proliferation index 
Pmp polymorphic membrane protein 
RB reticulate body 
RNA ribonucleic acid 
SFV Semliki Forest virus 
SPG sucrose-phosphate-glutamate 
TAP transporter associated with antigen processing 
TcR T cell receptor 
Th helper CD4+ T lymphocytes 
TNF tumor necrosis factor 
TTSS type III secretion system 
13
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original articles, which in the text are 
referred to by their Roman numerals. In addition, some unpublished data 
are presented.
I        Sarén A., S. Pascolo, S. Stevanovic, T. Dumrese, M. 
Puolakkainen, M. Sarvas, H.-G. Rammensee, and J. M. 
Vuola. 2002. Identification of Chlamydia pneumoniae-
derived mouse CD8 epitopes. Infection and Immunity 70:
3336-3343.
II           Tammiruusu A., A. Haveri, S. Pascolo, R. Lahesmaa, S. 
Stevanovic, H.-G. Rammensee, M. Sarvas, M. 
Puolakkainen, and J. M. Vuola. 2005. Clearance of 
Chlamydia pneumoniae infection in H-2 class I-/- human 
leucocyte antigen-A2.1 monochain transgenic mice. 
Scandinavian Journal of Immunology 62: 131-139.
III Penttilä T*., A. Tammiruusu*, P. Liljeström, M. Sarvas, 
P. H. Mäkelä, J. M. Vuola, and M. Puolakkainen. 2004. 
DNA immunization followed by a viral vector booster in a 
Chlamydia pneumoniae mouse model. Vaccine 22: 3386-
3394.
* equal contribution 
IV  Tammiruusu A., T. Penttilä, R. Lahesmaa, M. Sarvas, M. 
Puolakkainen, and J. M. Vuola. Intranasal administration of 
chlamydial outer protein N (CopN) induces protection 
against pulmonary Chlamydia pneumoniae infection in a 
mouse model.  Manuscript submitted.  
These articles are reproduced with the kind permission of their copyright holders.
14
1. INTRODUCTION 
Chlamydiae are perhaps the most successful obligate intracellular 
bacterial pathogens, causing a variety of infections in humans and 
animals. Chlamydia trachomatis (C. trachomatis) is not only the most 
common sexually transmitted bacterium but it also causes trachoma and 
blindness, affecting millions of people in endemic areas (Kasi et al.,
2004). Chlamydia pneumoniae (C. pneumoniae) is a respiratory pathogen 
of humans, and it infects the majority of humans around the world. 
Although chlamydiae were originally considered a small group of a few 
closely related bacteria characterized by a unique developmental cycle, it 
has become clear that chlamydial diversity and their distribution in nature 
is wider that thought.
C. pneumoniae causes relatively mild respiratory infections in young 
adults but may cause more severe lower respiratory disease e.g. 
pneumonia in older individuals. Virtually everyone is infected at some 
point in life, and reinfections are common. Moreover, C. pneumoniae
infections have a tendency to become persistent. Although the 
pathogenesis of persistent chlamydial infection is not well understood, an 
increasing body of data suggests an association between the persistence 
and severe pulmonary and cardiovascular consequences (Belland et al., 
2004). To avoid this common disease and its serious sequelae, a vaccine 
preventing the C. pneumoniae infection would be highly desirable and an 
attractive approach. However, there are several challenges in the 
development of an efficacious chlamydial vaccine. Specific elements of 
the host protective immunity against C. pneumoniae infection need to be 
defined more precisely, and a better understanding of immunogenic as 
well as pathogenic components of chlamydia is needed in order not to 
exacerbate unnecessary inflammation and tissue damage. 
The murine model of C. pneumoniae respiratory infection closely mimics 
the infection and disease in humans, therefore providing a relevant model 
for understanding host immunity to chlamydial infection. Since athymic 
mice are incapable of clearing C. pneumoniae pulmonary infection, T 
cells play an essential role in protection (Penttilä et al., 1999). 
Furthermore, mice lacking CD8+ T lymphocytes are more susceptible to 
infection than are immunocompetent mice or mice lacking CD4+ T 
lymphocytes, indicating that CD8+ T lymphocytes play a major role in 
protection against C. pneumoniae infection (Penttilä et al., 1999; 
Rottenberg et al., 1999). Stimulation of CD8+ cytotoxic T lymphocytes 
(CTL) requires that antigen presenting cells (APC) present pathogen-
15
derived peptides bound to major histocompatibility complex (MHC) class 
I molecules. With the help of the structural knowledge of MHC molecules 
and computational analysis of a protein antigen, candidate CD8 epitopes 
can be predicted from the protein sequence. Synthetic peptides can be 
identified as CD8 epitopes by testing for induction of a cytotoxic response 
after peptide immunization. Prior knowledge of the epitope specificity
provides an efficient method for analysing CD8+ T cell responses during 
immunization and infection, and enables the development of novel and 
highly specific preventive and therapeutic approaches against C.
pneumoniae infection.
A challenge in the vaccine development is the selection of an appropriate 
vaccine antigen that fulfills the immunogenic requirements; vaccine 
antigen(s) need to be safe, well tolerated, and able to induce long-lasting 
and strong protection to the greatest number of people. The selection of 
chlamydial antigens for vaccines has been problematic since there has 
been limited information on the specificity of the protective immunity. 
First candidate antigens were selected on the basis of their abundance in 
C. pneumoniae (major outer membrane protein, MOMP; outer membrane 
protein 2, Omp2) or capability to induce antibodies in humans (Omp2; 
heat shock protein 60, Hsp60). In addition, polymorphic outer membrane 
proteins (Pomps) and a component of type III secretion system 
(chlamydial outer protein N, CopN) were included in the investigation in 
this thesis. Recent progress in chlamydial genomics, proteomics and 
bioinformatics is expanding the pool of available vaccine candidates. 
An effective delivery system and adjuvant are needed to direct the 
immune responses to the mucosal sites of infection and boost the 
protective immunity. Naked DNA and a live viral vector encoding the 
desired proteins direct the antigens into the conventional MHC class I 
antigen presentation pathway and elicit a CD8+ T-cell response. Partial 
protection against C. pneumoniae pulmonary infection has been observed 
in mice vaccinated with DNA carrying a gene for MOMP (Penttilä et al.,
2000). To achieve more effective protection against chlamydial challenge, 
alternative immunization strategies including different forms of antigen 
(naked DNA, Semliki Forest virus, heat-treated protein antigens), 
combinations of different vehicles, and adjuvants were tested in this 
thesis. Descriptions of immunity from in vivo models, together with in 
vitro studies, provide a more coherent picture of interaction between 
chlamydia and the host cell. These findings and advances enable us to 
proceed to studying chlamydial pathogenesis and vaccine development. 
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2. REVIEW OF THE LITERATURE 
2.1. CHLAMYDIAE 
A characteristic chlamydial developmental cycle defines all members of 
the Chlamydiales order which is phylogenetically separated from all other 
known bacteria. The Chlamydiaceae family contains two important 
human pathogens C. trachomatis, the world’s major cause of preventable 
blindness and sexually transmitted disease, and C. pneumoniae which 
infects the majority of humans. Other species within genus Chlamydia are
C. psittaci which primarily infects birds and occasionally humans, and C.
pecorum isolated from ruminants, swine and koalas. Recently, a new 
taxonomy was proposed that increases the number of species in the 
Chlamydiaceae family to nine, and groups these species into two genera: 
Chlamydia and Chlamydophila (Everett et al., 1999; Bush et al., 2001) 
(Figure 1). However, since the new nomenclature has not been generally 
accepted and much debate continues on the issue, I have used the original 
designation, Chlamydia pneumoniae, for this thesis. 
Since the late 1990s, novel chlamydia-related bacteria have been 
discovered, including endosymbionts of amoebae and insects, and 
contaminants of a laboratory cell culture (reviewed by Corsaro et al.,
2003; Collingro et al., 2005). The existence of these environmental 
chlamydiae indicates a richer diversity and wide distribution of 
chlamydiae in nature, and has resulted in the description of three novel 
families within the order Chlamydiales: Parachlamydiaceae,
Simkaniaceae, and Waddliaceae (Everett et al., 1999; Rurangirwa et al.,
1999) (Figure 1). Future studies of these environmental chlamydiae may 
help to clarify their potential to cause human diseases, and to understand 
the evolution and unique biology of pathogenic chlamydiae. 
2.1.1. Chlamydia pneumoniae
C. pneumoniae is a very common respiratory pathogen of humans, and it 
is found worldwide. Based on seroepidemiologic studies, more than 50% 
of adults have antibodies against C. pneumoniae, and the seroprevalence 
reaches approximately 75% in the elderly (Kuo et al., 1995). C. 
pneumoniae is transmitted by aerosol droplets, and it causes a range of 
respiratory diseases, including pharyngitis, bronchitis, sinusitis, 
pneumonia and otitis media (Grayston, 1992). The majority of infections 
are mild or even asymptomatic, and occur most commonly in young 
adults. In the elderly C. pneumoniae may cause more severe respiratory 
diseases.
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Figure 1. Diagram of old versus new classification of the order 
Chlamydiales (Everett et al., 1999). The new taxonomy splits the former 
family Chlamydiaceae into two genera, Chlamydia and Chlamydophila
(like chlamydia), encompassing nine species. Three new non-
Chlamydiaceae families were added, the Parachlamydiaceae,
Waddliaceae and Simkaniaceae.
Old classification New classification
Parachlamydiaceae
Simkaniaceae
Waddliaceae
ChlamydiaceaeC. trachomatis
C. suis
C. muridarum
Ch. felis
Ch. caviae
Ch. pecorum
Ch. pneumoniae
Ch. abortus
Ch. psittaci
Chlamydia
Chlamydophila
Chlamydiacea
Chlamydia
C. trachomatis
C. pneumoniae
C. pecorum
C. psittaci
18
C. pneumoniae is able to infect and survive in a wide array of host cell 
types, including lung epithelium, macrophages, circulating monocytes, 
arterial smooth muscle cells and vascular endothelium (Kaukoranta-
Tolvanen et al., 1996; Gaydos et al., 1996). Reinfection and persistent 
infection are also recognized, and the contribution of these infections to 
chronic diseases has been intensively studied in recent years. C. 
pneumoniae has been strongly associated with cardiovascular disease and 
atherosclerosis as demonstrated by seroepidemiological studies showing 
higher anti-C. pneumoniae antibodies in patients with cardiovascular 
disease, detection of C. pneumoniae within atherosclerotic lesion by 
cultivation, immunohistochemistry, electron microscopy or polymerase 
chain reaction, and showing that C. pneumoniae has an atherogenic effect 
in animal models (reviewed by Leinonen et al., 2002; Belland et al.,
2004; de Kruif et al., 2005). The atherogenic mechanisms of C. 
pneumoniae are not known but many pathogenetic pathways have been 
proposed, including stimulation of monocyte migration to plaque, 
interference with lipid metabolism, and induction of inflammatory and 
immunopathogenic responses such as autoimmunity to Hsp60. In spite of 
some drawbacks in seroepidemiological studies and intervention trials 
(O’Connor et al., 2003; Grayston et al., 2005; Ieven et al., 2005), much 
evidence has accrued that C. pneumoniae is involved in cardiovascular 
disease and atherosclerosis (Leinonen et al., 2002; Belland et al., 2004). 
However, since atherosclerosis is a multifactorial and highly complex 
disease, the microbial pathogenesis theory for atherosclerosis still remains 
unproved. C. pneumoniae has also been associated with acute and chronic 
asthma but whether the infection is a cause of disease or effect from 
allergic response is not clear (reviewed by Hansbro et al., 2004). 
Additionally, C. pneumoniae has been proposed as the etiological agent of 
multiple sclerosis (Sriram et al., 1998) and Alzheimer’s disease (Balin et
al., 1998) but recent studies have been unable to corroborate these 
associations (Munger et al., 2004; Robinson et al., 2004). It remains 
possible, however, that the acute or chronic C. pneumoniae infections 
contribute to the progressive neurodegeneration seen in multiple sclerosis 
and Alzheimer’s disease.
2.1.2. Chlamydia trachomatis
C. trachomatis is responsible for about 15% of all cases of blindness and 
an estimated 600 million people live in regions where trachoma is 
endemic (Solomon et al., 2004). Moreover, C. trachomatis is one of the 
most common sexually transmitted bacterial agents throughout the world, 
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and it may increase the risk for infertility (Land et al., 2002). The major 
problem in the control of genital tract chlamydia infections is that 
infections are frequently asymptomatic. C. trachomatis lymphogranuloma 
venereum and trachoma biovars infect humans and are closely related, 
whereas Chlamydia muridarum (formerly known as C. trachomatis mouse 
pneumonitis agent, designated MoPn) is found in mice. 
Lymphogranuloma venereum serovars (L1, L2, L2a, and L3) are sexually 
transmitted and rare in developed countries, and by penetrating the 
submucosa cause a more systemic illness and lymphadenopathy. 
Trachoma serovars A, B, Ba, and C are usual ocular isolates from 
trachoma patients, while serovars D to K, Da, Ia, and Ja are typically 
associated with genital tract diseases including urethritis, cervicitis, pelvic 
inflammatory disease, with sequelae infertility, neonatal conjunctivitis 
and pneumoniae, and arthritidis (Solomon et al., 2004). C. trachomatis 
strains are not strictly tissue specific, and the genital serovars are 
occasionally found in the eye and vice versa. C. muridarum has been used 
in experimental models for studying C. trachomatis infections in mice. 
2.1.3. Structure 
Chlamydiae have a small genome; 1 230 230 base pairs (bp) chromosome 
of C. pneumoniae is slightly larger (187 711 bp) than that of C.
trachomatis (Kalman et al., 1999). However, C. trachomatis has a 
plasmid (7 493) lacking in the strains of C. pneumoniae. Comparisons of 
chlamydial genomes have revealed apparent low level of DNA homology 
between C. pneumoniae and C. trachomatis, and may explain the unique 
properties of each species in the disease spectrum. 214 protein-coding 
sequences are exclusive to C. pneumoniae and not found in C.
trachomatis, including chlamydial polymorphic membrane proteins 
(Pmps), proteins for purin and biotin biosynthesis and a homologue for an 
aromatic amino acid hydroxylase (Kalman et al., 1999). Of the 70 C.
trachomatis genes not represented in C. pneumoniae genome, most are 
classified as hypothetical proteins, and the remaining genes consist of the 
tryptophan operon, thiol protease genes and phospholipase-D-like genes 
(Kalman et al., 1999). An unexpectedly high number of chlamydial genes 
is related to higher organisms like plant chloroplasts, suggesting close 
relationship between chlamydiae and a cyanobacterial ancestor of the 
chloroplast (Brinkman et al., 2002). 
All chlamydial species are gram-negative bacteria containing rough-type 
lipopolysaccharide (LPS) that has only weak endotoxic activity (Stephens, 
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1999). Chlamydiae have little or no detectable peptidoglycan although 
they have the genes needed for peptidoglycan synthesis. The rigidity and 
osmotic stability of chlamydial cell wall are thought to be conferred by 
the chlamydial outer membrane complex (COMC) which is composed 
primarily of major outer membrane protein, MOMP (40 kDa), cysteine 
rich outer membrane proteins, Omp2 (60 kDa) and Omp3 (12 kDa), and 
polymorphic membrane proteins (Pmps). The main components of the 
COMC appear to be extensively cross-linked, forming disulfide bonds 
with each other thereby strengthening the envelope (Hatch, 1996). The 
MOMP protein functions as a membrane-spanning porin, which is 
permeable to adenosine triphosphate (ATP), and is present in both 
developmental forms of chlamydia, an elementary body (EB) and a 
reticulate body (RB). In C. trachomatis, unlike in C. pneumoniae MOMP 
encoding gene (ompA) exhibits DNA sequence variation, and is widely 
used to distinguish C. trachomatis strains. Since C. trachomatis MOMP is 
an abundant and immunodominant protein capable of inducing 
neutralizing antibodies, it has been the prime candidate for the chlamydial 
vaccine development, and both B and T cell epitopes have been identified 
in C. trachomatis MOMP (Stephens, 1999; Cunningham et al., 2003). 
Previously, the MOMP protein was not believed to be surface exposed in 
C. pneumoniae because the sera from C. pneumoniae-infected patients or 
mice demonstrated only weak reactivities with MOMP, and the antibodies 
specific for recombinant MOMP did not bind to purified EB (Campbell et
al., 1990; Airaksinen et al., 2003; our unpublished finding). However, it 
has been suggested that certain domains of MOMP are exposed on the 
surface of C. pneumoniae but the sera against denatured recombinant 
proteins cannot recognize a conformational epitope of MOMP and vice 
versa (Wolf et al., 2001b).  In addition, the sera from C. pneumoniae-
immune patients are able to recognize species-specific regions within C. 
pneumoniae MOMP when the protein is dissected into the recombinant 
fragments according to its extracellular domains (Klein et al., 2003). C.
pneumoniae MOMP contains CD8+ T cell epitopes but no CD4+ T cell 
epitopes have been found in mice (Wizel et al., 2002; Mygind et al.,
2004). The MOMP protein, MOMP-derived peptides and DNA encoding 
for MOMP as components for a chlamydial vaccine induce a T helper 
type 1 (Th1) response but only partial immunity against chlamydial 
infection (Knight et al., 1995; Murdin et al., 2000; Penttilä et al., 2000; 
Eko et al., 2004).
Omp2 (OmcB) and Omp3 (OmcA) are cysteine-rich proteins that are 
localized to the inner surface of the outer membrane and are present in 
greatest amounts in EB. Omp2 is highly conserved within a chlamydial 
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species but shows variability between the different chlamydial species 
(Portig et al., 2003). Omp2 is likely an immunodominant antigen, and in 
C. trachomatis a small amino terminal portion of Omp2 is exposed at the 
surface of EB (Stephens et al., 2001). Although a strong antibody 
response against Omp2 appears during C. pneumoniae infection, the 
Omp2 protein is not detected on the surface of C. pneumoniae and the 
Omp2-specific antibodies are unable to neutralize the bacteria (Watson et
al., 1994; Mygind et al., 1998; Airaksinen et al., 2003). T cell epitopes 
have been identified within the Omp2 protein (Curry et al., 2000; Goodall 
et al., 2001; Gervassi et al., 2004). 
The chlamydial genome sequencing revealed a novel family of 
polymorphic membrane proteins (Pmps) with sizes around 100 kDa. Nine 
genes were found in C. trachomatis and even 21 genes in C. pneumoniae 
(Kalman et al., 1999). Comparison of the Pmp sequences has shown a 
large amount of heterogeneity between C. pneumoniae and C. trachomatis 
(Grimwood et al., 1999). Although the expression of Pmp genes varies 
between different C. pneumoniae strains and even within a strain 
(Pedersen et al., 2001), several Pmp proteins are heavily up-regulated at 
the time of conversion of RB to EB, and at least ten Pmps are present in 
EB. It is likely that Pmp6, 8, 10, 11 and 21 are surface exposed in C.
pneumoniae (Vandahl et al., 2002). A recent study showed that the 
Pmp21 protein mediates adhesion of C. pneumoniae EB to the host cell, 
and induces activation and cytokine release from human monocytes 
(Wehr et al., 2004). In addition, the anti-Pmp21 antibodies reduce 
chlamydial infectivity. Some of the Pmp proteins such as Pmp8, 20 and 
21 are consistently recognized by CD4+ T cells during C. pneumoniae
infection in mice (Mygind et al., 2004).
2.1.4. Developmental cycle 
Chlamydiae have two major developmental forms; small (0.3 μm)
infectious elementary body (EB) and larger (1 μm) vegetative reticulate 
body (RB). Metabolically inert EB is adapted for extracellular survival 
and is able to trigger very rapid and efficient internalization by a 
eukaryotic cell. Specific ligands on the EB surface and host receptors that 
mediate entry are still uncertain. Heparin and heparan sulphate found on 
the surface of most nucleated cells competitively inhibit C. pneumoniae
infectivity, as a result from the binding of heparin to the bacterium 
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(Wupperman et al., 2001). It has been proposed that chlamydiae bind 
directly to the cell-derived heparan structures at the surface of the host 
cell (Su et al., 1996), or  that chlamydiae synthetize their own heparan 
sulphate-like structure which coats their surface and acts as a bridge 
between the chlamydial envelope and the host cell heparan receptor 
(Stephens, 1999). Although the heparan sulphate does have an effect on 
infectivity, the actual role of these negative charged glycosaminoglycans 
is controversial. One view is that the inhibitory effect is charge-mediated 
and indirect, stabilizing the bacterium on the host cell surface and 
enabling more specific interaction with other unidentified receptors 
(Stephens, 1999). At least two chlamydial proteins on the EB surface have 
been suggested as glycosaminoglycan-binding adhesins; MOMP (Su et
al., 1996) and Omp2 (Stephens et al., 2001). 
Chlamydiae have been reported to enter host cells by both a clathrin-
dependent pathway and a clathrin-independent pathway including a raft-
mediated process (reviewed by Dautry-Varsat et al., 2004). Lipid rafts are 
specialized dynamic, detergent-resistant regions of the plasma membrane 
enriched in cholesterol, glycosphingolipids, glycosylphosphatidylinositol-
anchored proteins, and some membrane proteins, including caveolin and 
molecules involved in signal transduction (Simons et al., 2002). Several 
pathogens including Mycobacterium tuberculosis, Salmonella typhi, the 
influenza virus and HIV have been reported to interact with eukaryotic 
cells via raft microdomains (reviewed by Simons et al., 2002 and Gulbins 
et al., 2004). Raft-disrupting agents can inhibit the C. pneumoniae and C.
trachomatis L2 infection of cultured epithelial cells (Stuart et al., 2003; 
Jutras et al., 2003). However, these drugs have pleiotropic effects on 
membrane processes, and recent results argue against an exclusive role of 
rafts-mediated entry for C. trachomatis L2 infection (Gabel et al., 2004).
It is most likely that the chlamydial attachment and entry are dynamic 
processes involving multiple receptors and mechanisms. Carabeo and 
coworkers recently showed that the internalization of C. trachomatis is 
dependent on host Rac GTPase (Rho GTPase family member) and an 
active actin remodelling process, which leads to the formation of a 
pedestal-like structure at the site of attachment (Carabeo et al., 2002;
Carabeo et al., 2004). These actin pedestal are reminiscent of pedestal
formation by enteropathogenic and enterohemorrhagic Escherichia coli,
enteric pathogens that regulate their attachment and entry in a type III 
secretion-dependent manner. Correspondingly, the actin remodelling 
process on chlamydial entry is most likely due to a translocated actin-
recruiting protein (Tarp) which is directed into the host cell by a type III 
secretion system and tyrosine-phosphorylated once exposed to the host 
cytoplasm (Clifton et al., 2004). These observations suggest that C.
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trachomatis might induce its own uptake by triggering signalling 
pathways of the host cell that culminates in actin recruitment and 
endocytosis. Interestingly, the Tarp gene is present in all of the sequenced 
chlamydial genomes but the potential phosphorylation sites within the 
protein are different among chlamydial species and strains (Clifton et al.,
2004).
Upon uptake, differentiation and multiplication of chlamydiae take place 
in a membrane-bound compartment, referred as an inclusion, which 
separates from the endocytic pathway and avoids the phagolysosomal 
fusion. EB differentiates into RB form that replicates by binary fission. 
The inclusion enlarges by intercepting membrane vesicles exocytosed 
from the Golgi. After the multiplication RB rearrange back to EB forms 
that are released from the host. The growth cycle lasts from 32 to 72 h, 
depending on the chlamydial species and growth conditions (Stephens, 
1999).
In addition to the acute development cycle, chlamydiae can also persist in 
the host cell. Persistent chlamydial infection is associated with an 
incomplete growth cycle characterized by structurally abnormal RB. The 
aberrant forms of chlamydia can be transferred to new daughter cells at 
cell division, and C. pneumoniae infection has been maintained for three 
years in cell culture (Stephens, 1999). Reverse transcriptase PCR studies, 
microarrays, and proteomics studies have revealed that chlamydiae have 
differential transcription profiles during the acute and persistent infection 
(Mathews et al., 2001; Belland et al., 2003; Hogan et al., 2003; Hogan et
al., 2004). The persistent stage of chlamydial infection can be induced in 
vitro by a variety of factors, including IFN-γ, antibiotics or iron depletion 
(reviewed by Hogan et al., 2004). Many in vivo conditions could also 
result in metabolic stress or IFN-γ production causing chlamydia to switch 
to the persistent state. In addition to the paradigm of persistence as a 
general stress response, another possibility is that persistence is an 
alternative life cycle used by chlamydiae to avoid the host immune 
response. The reduced metabolic activity associated with incomplete 
growth may render the chlamydiae less accessible to antibiotic treatment 
but still capable of inducing inflammation. Although the persistent 
chlamydial infections are particularly associated with pathology, the 
actual role of these infections in chronic diseases is still open. At least two 
hypotheses for chlamydial pathogenesis, how it causes 
immunopathological disease, have been proposed (Stephens, 2003). 
According to the traditional view, the disease is mediated by antigen-
dependent adaptive immune responses such as delayed-type 
hypersensitivity and autoimmune molecular mimicry. An alternative 
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cellular pathogenesis hypothesis is that the chlamydial pathogenesis is 
based on innate cellular responses of non-immune cells infected with 
chlamydiae. The chlamydia-infected cells produce proinflammatory 
cytokines and other modulators that can promote cellular proliferation, 
tissue remodelling and scarring (Stephens, 2003).  
2.1.5. Inclusion membrane 
Chlamydiae interact with the host cell across the surrounding inclusion 
membrane. The chlamydial inclusion membrane is originally formed by 
the invagination of the plasma membrane which is, within a few hours 
following endocytosis, actively modified by the chlamydiae. Endocytosed 
EB are rapidly transported to the Golgi region where they interact with an 
exocytic pathway in a process which requires chlamydial transcription 
and translation activity. Golgi-derived sphingomyelin and cholesterol-
containing vesicles fuse with the chlamydial inclusion enabling 
enlargement of the inclusion during replication (Wolf et al., 2001a; 
Scidmore et al., 2003; Carabeo et al., 2003). The C. pneumoniae inclusion 
membrane, like the inclusion membrane of other chlamydial species, does 
not contain endosomal or lysosomal markers (Al-Younes et al., 1999). 
Actually, no host cell proteins are known to be inserted into the inclusion 
but chlamydiae selectively recruit certain host cell proteins to the 
inclusion, including Rab-GTPases, components of host membrane 
trafficking machinery (Rzomp et al., 2003). In contrast, several 
chlamydial proteins have been found in the inclusion membrane, 
including a large family of Inc proteins which are unique to chlamydiae. 
90 and 36 Inc-like open reading frames have been found in C.
pneumoniae and C. trachomatis, respectively (Toh et al., 2003). While 
Inc genes are conserved among chlamydiae, the members of Inc family 
share only little identity with each other or with any other proteins. A 
common structural feature of all Inc proteins, however, is that they 
possess a large hydrophobic domain which is probably required for 
insertion into the inclusion membrane (Bannantine et al., 2000). The first 
member of the Inc family to be identified, IncA, accumulates strongly to 
the inclusion membrane (Figure 2A). A type III secretion system (TTSS) 
has been proposed to secrete IncA proteins into the inclusion membrane 
where they probably have a role in the homotypic fusion of inclusions in 
C. trachomatis (Delevoye et al., 2004). However, C. pneumoniae is less 
fusogenic but still expresses IncA, indicating the unidentified other roles 
of IncA. Other proteins localized to the inclusion membrane are 
chlamydial outer protein N (CopN) and class 1 accessible protein (Cap1) 
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(reviewed by Rockey et al., 2002) and cysteine rich protein A (CrpA) 
(Starnbach et al., 2003). The CopN protein is supposed to be the lid of 
TTSS apparatus in the inclusion membrane regulating the gating function 
of TTSS (Fields et al., 2000). C. trachomatis Cap1 and CrpA are CD8+ T 
cell targets but their function remains unknown (Fling et al., 2001; 
Starnbach et al., 2003).
A                                                                      B
Figure 2. Immunofluorescence images of C. pneumoniae infected HL 
cells stained with antisera generated against IncA (A) and CopN (B) 
showing the localization of the proteins within inclusions.
2.1.6. Type III secretion system  
Several pathogenic gram-negative bacteria share a type III secretion 
system (TTSS) that enables the efficient transfer of effector proteins from 
the bacterium into the host cytosol. Over two decades ago needle-like 
surface projections were observed on the surface of EB and RB 
(Matsumoto, 1981), and later it was suggested that these structures 
resemble the type III secretion apparatus described in many gram-
negative bacteria (Bavoil et al., 1998). Unlike clustered TTSS genes in 
other bacteria, chlamydial TTSS genes are scattered throughout the 
chromosome, and expressed mainly in the middle to late stage of the 
developmental cycle (Fields et al., 2000). The TTSS of C. pneumoniae is
composed of 13 proteins, including structural components, ATPase and 
chaperones (Lugert et al., 2004; Slepenkin et al., 2005) and the 
functionality of TTSS has been presented at different stages during the 
chlamydial developmental cycle (Fields et al., 2003). Chlamydial TTSS 
may have a role both extracellularly when the EB comes into contact with 
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the host cell and intracellularly when the effector proteins are secreted 
into the host cytosol or embedded into the inclusion membrane. TTSS-
secreted effector proteins are a heterogeneous group and appear to be 
unique to the different pathogens. Several effector proteins secreted by 
chlamydiae have been identified but only little is known about their 
function (Subtil et al., 2005). In addition to the Inc proteins and actin -
recruiting protein Tarp, CopN is a promising candidate to be delivered by 
the TTS machinery. The CopN protein is suggested to be an equivalent to 
YopN, a TTSS-secreted protein of the Yersinia species. CopN is supposed 
to be present in EB, RB and whole-culture extracts (Fields et al., 2000) 
(Figure 2B).
2.1.7. Apoptosis 
Infected cells frequently undergo programmed cell death, apoptosis, thus 
preventing the spreading of the pathogen. Apoptotic cells are removed 
efficiently but without inflammation by the immune system. However, 
like many other intracellular pathogens, chlamydiae are able to modulate 
the apoptotic pathways in the infected host cell. Both anti- and 
proapoptotic activities have been reported to occur during chlamydial 
infection depending on the circumstances (reviewed by Byrne et al.,
2004). Resistance to apoptosis may favour the growth of chlamydiae, 
since infected cells cannot destroy themselves even if heavily infected. In 
general, C. pneumoniae infected cells are resistant to apoptosis induced 
by treatment with drugs or by death receptor ligation (Geng et al., 2000;
Rajalingam et al., 2001; Fischer et al., 2003). In a recent study, none of 
the 17 different serovars and strains from C. trachomatis and C. psittaci
species was able to induce apoptosis in human cell lines, but the 
antiapoptotic ability varied between strains (Greene et al., 2004). 
However, studies using C. trachomatis-infected cell cultures have shown 
that when the infected cells are resistant to apoptosis, significant apoptosis 
can be detected in the nearby uninfected cells (Schöier et al., 2001; 
Greene et al., 2004). This can be due to the proapoptotic activity of 
cytokines such as tumor necrosis factor alpha (TNF-α) derived from the 
chlamydia-infected cells (Jendro et al., 2004). It has been suggested that 
chlamydiae may evade the host defence by inducing apoptosis of 
leukocytes recruited to the site of infection. On the other hand, at the end 
of the developmental cycle chlamydiae must exit the infected cell, and 
both apoptotic and necrotic mechanisms have been detected during host 
cell lysis (Jungas et al., 2004; Dumrese et al., 2005). Consequently, the 
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type of cell death depends on the chlamydial strain, developmental stage 
and also on host cell type and the particular environmental condition. 
2.1.8. Mouse model for C. pneumoniae infection 
The C. pneumoniae mouse model resembles the human infection and 
provides a tool for studying pulmonary infection in more detail. The
susceptibility of different mouse strains to C. pneumoniae infection 
varies. NIH/S and Swiss Webster mice are highly susceptible, followed 
by C57BL/6 mice, whereas BALB/c mice are more resistant (reviewed by 
de Kruif et al., 2005). Furthermore, the infectious dose has to be 
established for each C. pneumoniae strain because differences exist in 
virulence. Intranasal inoculation of mice leads to self-limited pulmonary 
infection. Symptoms, like dyspnoea, weight loss, and tangled coat, 
depend on the dose given and reach a maximum within a couple of days. 
When the immunocompetent BALB/c mice are infected with 106 IFU, the 
infection in lungs peaks at approximately 104-105 IFU/lung during the first 
week with no overt symptoms, after which the number of cultivable 
bacteria starts to decrease, and at 3-4 weeks after infection no bacteria can 
be cultured from the lung (Penttilä et al., 1998). Histological studies have 
revealed peribronchial and perivascular inflammation with mononuclear 
cell infiltration within two weeks after the first challenge (Kaukoranta-
Tolvanen et al., 1993; de Kruif et al., 2005). C. pneumoniae primary 
infection in BALB/c mice induces an acquired immunity and partial 
protection, since faster and more efficient clearance of bacteria is detected 
after subsequent rechallenge (Penttilä et al., 1998). However, the 
histopathological changes during reinfection are similar to those detected 
after primary infection, except for the stronger lymphoid reaction (Penttilä 
et al., 1998) indicating the development of immunological memory and 
accumulation of chlamydia-specific lymphoid cells to the site of infection. 
Following the local infection in lungs, C. pneumoniae is able to spread to 
other organs throughout the body, including aorta and spleen (Moazed et
al., 1997). Infected macrophages and blood monocytes are thought to 
transport chlamydiae from the respiratory tract to the other tissues 
(Moazed et al., 1998). In contrast to the isolation of viable organisms 
from the lungs, C. pneumoniae antigens and DNA can be detected in the 
lungs for a longer period, up to 20 weeks after infection (Moazed et al.,
1997). Furthermore, by using immunosuppressive treatments, pulmonary 
infection can be reactivated in culture-negative NIH/s mice (Laitinen et 
al., 1996) suggesting a latent persistence of C. pneumoniae bacteria in 
mice.  
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Recently, it has been suggested that the chlamydial strains have evolved 
pathogen-specific mechanisms to avoid the immune response of their 
natural hosts, thereby the same strain may not be controlled by identical 
immune mechanisms in different hosts (Caldwell et al., 2004; Igietseme 
et al., 2004). E.g. murine strains are more resistant to antibicrobial action 
of IFN-γ than human strains in murine cells. IFN-γ induces the expression 
of indolamine-2,3-dioxygenase (IDO) and p47 GTPases in the human and 
mouse cells, respectively, and these effector molecules inhibit the 
chlamydial growth in different ways (Beatty et al., 1994; Caldwell et al.,
2004). However, the human and murine strains have co-evolved specific 
mechanisms for inactivating these host responses; the human strains 
circumvent the IDO-mediated tryptophan deprivation with the help of 
tryptophan synthase genes, and the murine strains possess GTPase 
inactivating proteins (Caldwell et al., 2004). The development of a more 
humanized mouse model (e.g. transgenic mouse model in which GTPase 
genes are knocked out and human IDO gene introduced) may be needed 
in order to achieve a more reliable system for testing and evaluating 
human vaccines in mice. 
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2.2. IMMUNE RESPONSE TO CHLAMYDIAE
Chlamydia and its intracellular location challenge the host immune 
system. Undoubtedly, multiple elements, including innate response and 
adaptive immunity control the growth and spread of chlamydiae during
infection. The relative contribution of the different arms of the immune 
system to the resolution of chlamydial infection has been intensively 
studied in multiple animal models, and is complicated not only by the 
different animal species but also by the different animal and human 
strains of Chlamydia and the site of infection (experimental genital, ocular 
and respiratory infections). In spite of some controversies that remain to 
be resolved, the current view is that various cell types are primed and 
work in resistance to chlamydia, including dendritic cells (DC) and other 
antigen presenting cells (APC), B lymphocytes, mucosal and circulating 
antibodies, CD4+ and CD8+ T lymphocytes, and cytokines, especially 
IFN-γ which orchestrates the whole network.
2.2.1. Antigen presenting cells
The cells that display MHC-associated peptides are called antigen 
presenting cells (APC), and they are required for T cell activation. A large 
variety of professional and nonprofessional APC present antigens both 
during the recognition phase of the immune system to initiate the immune 
response and during the effector phase to trigger the mechanisms needed 
for eliminating the pathogen. The CD8+ T cells recognize peptides bound 
to the class I MHC molecules which are constitutively expressed on 
virtually all nucleated cells. MHC I molecules present peptides derived 
mainly from cytosolic antigens (endogenous antigens) such as viral and 
tumor antigens. The ubiquitous expression of class I molecules allows 
CD8+ T cells to recognize and eliminate any type of infected or tumor 
cells. CD4+ T cells recognize peptides bound to class II MHC molecules 
which are expressed on professional APC, mainly on dendritic cells, but 
also macrophages, B cells and endothelial cells. In addition to antigen 
processing, certain APC provide costimulatory signals that are required 
for the full response of the T cells. In the respiratory tract, at the site of C. 
pneumoniae infection, APC are present in abundance.  
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2.2.1.1. Dendritic cells 
Dendritic cells (DC) are professional APC specialized to capture and 
process antigens eliciting the cellular immune response. Different 
subpopulations of DC exist throughout the body, especially on the skin 
and in mucous membranes where they interact with the environment. A 
central importance of DC is their role in linking innate immunity and 
antigen-specific adaptive immunity. DC like other innate immunity cells 
recognize microorganisms through pattern recognition receptors, 
including mannose receptor (Stahl et al., 1998) and Toll-like receptors 
(TLR) (Hemmi et al., 2000; Gordon, 2002). In the immature stage (i.e. 
not fully potent to prime T cells), DC uptake and process the antigen very 
efficiently but express fewer accessory molecules. Mature DC, in 
contrast, express MHC molecules and costimulatory molecules such as 
CD40, CD54 and B7 (CD80 and CD86) with high density (Inaba et al.,
1994; Caux et al., 1994). The matured DC migrate to lymph nodes or 
spleen where they stimulate other cells of the immune system. Dendritic 
cells unlike other APC are able to prime naive T cells, initiating the T cell 
response (Banchereau et al., 1998). Once activated, T cells can interact 
with other APC such as B lymphocytes and monocytes to perform 
effector functions that eliminate the antigen. Findings that DC can present 
antigens from apoptotic cells indicate that tumor cells and intracellularly 
infected cells incapable to prime immunity by themselves can be 
presented with the help of DC (cross-priming) (Albert et al., 1998, 
Larsson et al., 2001). 
Chlamydia antigens among others are processed and presented by 
dendritic cells and induce immune responses in mouse models. 
Recognition of C. pneumoniae in DC is dependent mainly on TLR2 
(Prebeck et al., 2001). The contact with C. pneumoniae leads to the 
maturation of DC indicated by upregulation of MHC and costimulatory 
molecules, activated nuclear factor κB (NF-κB) and secreted 
proinflammatory cytokines (Su et al., 1998; Shaw et al., 2001). 
Adoptively transferred DC pulsed with the nonviable C. trachomatis are 
able to induce a Th1 response and protection against chlamydial genital 
infection (Su et al., 1998; Shaw et al., 2001). In contrast, C. trachomatis-
infected DC fail to prime CD8+ T cells in vivo following adoptive 
transfer indicating that the directly infected DC present insufficient levels 
of chlamydial antigens and costimulatory molecules (Steele et al., 2004). 
For this reason cross-priming is believed to be especially important during 
the natural C. trachomatis infection; the infected epithelial cells could 
serve as a source of chlamydial antigens for cross-presentation by DC. 
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Although routine use of ex vivo antigen-pulsed DC as a vaccine for 
humans is unrealistic, dendritic cells provide a useful model by which 
protective chlamydial antigens and peptides can be defined. However, 
caution is needed when comparing in vitro and in vivo studies; adoptive 
transfer studies in C57BL/10 mice have revealed that DC pulsed with 
chlamydial major outer membrane protein (MOMP) induced an adverse 
Th2 type response rather than a protective Th1 type response expected on 
the basis of in vitro observations (Shaw J. et al., 2002). DC also populate 
atherosclerotic lesions but their role in the regulation of immune reactions 
in atherosclerosis needs further clarification (Bobryshev et al., 2004). 
2.2.1.2. Macrophages 
Macrophages are mononuclear leukocytes distributed throughout the body 
and are responsible for the first level defence mechanisms during 
infection. Highly phagocytic macrophages respond to antigens and 
microbial stimulus by capturing and eliminating pathogens as well as 
necrotic and apoptotic cells. Macrophages process and present antigens, 
and secrete chemokines and cytokines boosting or limiting other immune 
functions.
Chlamydiae are capable of infecting and surviving in mononuclear cells. 
Inhibition of phagolysosomal fusion and survival of chlamydiae in the 
macrophages is unclear. Different chlamydia species use different 
receptors for entry into the macrophages; the mannose-receptor has a role 
for the entry of C. trachomatis into the murine macrophages, C. psittaci
infects macrophages with or without mannose-receptors while C. 
pneumoniae infects mannose-receptor negative cells better than mannose-
receptor positive cells (Kuo et al., 2002). Immunohistological and 
electron microscopy analysis of mice have revealed that after intranasal C. 
pneumoniae challenge, the bacteria can be recovered from spleen and 
peritoneal macrophages in addition to lung (Yang et al., 1994; Yang et
al., 1995; Moazed et al., 1998). The antiapoptotic influence of C.
pneumoniae infection in the macrophage cell line was observed in an in 
vitro study (Airenne et al., 2002). This ability of chlamydiae to infect and 
survive in macrophages provides a mechanism by which chlamydiae may 
establish a chronic infection and disseminate. On the other hand, the 
infected host cells try to restrict the growth of an intracellular invader. 
Studies of C. pneumoniae-infected human monocytes showed that the 
morphology of the inclusions and chlamydial particles was abnormal 
indicating poor development of EB (Airenne et al., 1999). TNF-α
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secreted by alveolar macrophages in response to C. pneumoniae infection 
may be at least one reason for the incomplete development cycle and 
inhibition of viable progeny (Haranaga et al., 2003). Since there is poor 
replication of chlamydia within macrophages, infected macrophages do 
not appear to be particularly effective APC, and it seems more likely that 
DC via a mechanism of cross-presentation are more effective as APC in 
chlamydial infection (Steele et al., 2004).
Macrophages are considered to be one of the inflammatory mediators in 
the atherosclerotic process. By releasing a wide range of bioactive 
compounds, including cytokines, colony stimulating and growth factors, 
proteases, lipases and reactive oxygen intermediates, activated 
macrophages have a pathogenic potential to be involved in atherogenesis. 
C. pneumoniae has been detected both in circulating monocytes and in 
macrophages present in the atherosclerotic vascular wall. Recent studies 
suggest the role of C. pneumoniae for monocyte recruitment; by 
activating adhesion receptor system, C. pneumoniae may have an impact 
on monocyte adhesion and migration to the vessel wall (May et al., 2003). 
2.2.2. Natural killer (NK) cells 
NK cells, a part of the innate immune system, mediate cellular 
cytotoxicity via perforin/granzyme pathway, and secrete several cytokines 
including IFN-γ and TNF-α. In NK cells, the cytotoxic granules are 
preformed during NK cell development, and the cells can thus be 
activated within minutes of the first stimulation. NK cells kill efficiently 
tumor cells, and they are also important in immune responses to a number 
of intracellular bacterial and viral infections, especially during the early 
phases of infection. NK cells kill cells that have lost, or underexpress, 
MHC class I molecules. NK cells are lymphocytes, but unlike the B and T 
cells, NK cells use a multiple receptor recognition strategy. NK activity 
can be triggered through various combined receptors, with different 
structures and specificities (reviewed by Moretta et al., 2004). NK cells 
are either activated or inhibited when they interact with the target cell, 
depending on the ligands presented by the target cell. Remarkably, NK 
cells seem to have a predominant role in bridging the innate and adaptive 
immunity. Crosstalk between NK cells and DC leads to the polarization of 
DC during maturation or lysis of DC, and subsequent influence on the T 
cell responses (Raulet, 2004).
The involvement of NK cells in the control of chlamydial infection is not 
clear. The resistance of mice to C. pneumoniae was not altered after 
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depletion of NK cells using neutralizing antibodies (Rottenberg et al.,
2000). Furthermore, a T, B, and NK cell-deficient mouse strain showed 
similar levels of C. pneumoniae than the T and B cell-deficient mice 
(Rothfuchs et al., 2004). In contrast, NK cells appear quickly in the site of 
infection and participate in the control of C. trachomatis MoPn infection 
in mice (Tseng et al., 1998). Recent data show that the human NK cells 
are able to respond to C. trachomatis in vitro as assessed by IFN-γ
production and target cell lysis (Hook et al., 2004). The possible 
mechanism underlying the susceptibility to the NK cell-mediated lysis 
conferred by chlamydia is the reduced expression of MHC class I 
molecules. C. trachomatis may prevent its own presentation by degrading 
a transcription factor RFX-5, which is responsible for the synthesis of 
class I and class II MHC molecules (Zhong et al., 2001). A secreted 
chlamydia protease (chlamydial protease- or proteasome like activity 
factor, CPAF) which is responsible for this degradation, is also detected in 
C. pneumoniae and other chlamydiae (Shaw, A. et al., 2002; Dong et al.,
2005).
2.2.3. B lymphocytes and antibodies 
B lymphocytes comprise a major component of the adaptive immune 
system, having the exclusive ability to produce and secrete 
immunoglobulins (Ig) of various forms (isotypes). B lymphocytes 
effectively use the antigen-specific B cell receptor (BcR) to capture and 
concentrate antigens in class II compartments in lymphoid tissue. 
Antibody responses to protein antigens require interactions between 
antigen-specific B and T cells, including CD40-CD40L interactions and T 
cell-derived cytokines. Fully activated B cells also function in antigen 
presentation and production of a variety of cytokines and chemokines, and 
there is growing interest in the capability of B cells to modulate other 
immune responses. Activated B cells produce an array of effector 
cytokines that either promote (e.g. TNF-α, IL-6 and lymphotoxin) or 
suppress (IL-10) the immune responses (Burke et al., 2004; Duddy et al.,
2004).
As in most microbial infections, both specific humoral and cell-mediated 
immune responses are elicited following chlamydial infection. During 
experimental infection, systemic C. pneumoniae-specific IgG antibodies 
(Kaukoranta-Tolvanen et al., 1995) as well as mucosal IgA antibodies 
(Penttilä, 2004) are detected early after infection. Several C. pneumoniae-
derived proteins recognized by convalescent sera have been identified in 
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EB (Essig et al., 1999; Campbell et al., 2001; Penttilä, 2004). However, 
the contribution of chlamydia-specific antibodies to protection remains 
undefined. Intraperitoneally transferred C. pneumoniae-specific 
antibodies (either from immunized or convalescent mice) have resulted in 
partial protection to infection in NIH/S mice (Kaukoranta-Tolvanen et al., 
1995). The dose-dependent effect of the passively administered antisera 
suggests that antibodies may be responsible for the decrease of the 
amounts of bacteria. However, marked histological findings detected in 
the lung of the antisera treated mice indicate that antibodies cannot hinder 
inflammatory reactions. Furthermore, passively transferred convalescent 
serum of NIH/S mice did not protect the T cell-deficient nude mice or 
BALB/c mice against subsequent challenge (Penttilä et al., 1999), 
indicating a minor role for the serum antibodies. However, the presence of 
mucosal IgA antibodies against C. pneumonia correlates with the 
protection level; the mice with highest mucosal IgA levels also show the 
lowest bacterial counts in the lung (Penttilä, 2004). C. trachomatis studies 
have demonstrated that the role of antibodies in chlamydial immunity 
may be indirect – to promote Th1 type response via Fc receptor-mediated 
antigen uptake and processing, and activating Th1 cells in mice (Moore et
al., 2003). 
The role of B cells in antigen presentation or role of B cell-derived 
cytokines in chlamydial infections is not defined. The abundance of B 
cells at the infected site e.g. in the lung of C. pneumoniae-infected mice 
(Penttilä et al., 1998) and their importance in modulating T cell responses 
against C. trachomatis MoPn and other intracellular microbes (Yang et
al., 1998a; Shen et al., 2003) suggest that B cells themselves may very 
well be important against C. pneumoniae infection.
2.2.4. T lymphocytes 
The cellular immune response is executed by helper CD4+ T lymphocytes 
(Th) and cytotoxic CD8+ T lymphocytes (CTL) that recognize antigens 
associated with the MHC molecules with their antigen specific αβ T cell 
receptors (TcR). CD4+ T cells are the major regulatory cells that act on 
other cells of the immune system to promote various aspects of the 
immune response, including immunoglobulin isotype switching and 
affinity maturation of the antibody response, macrophage activation, and 
enhanced activity of NK cells and CD8+ T cells. In response to antigenic 
stimulation CD4+ T cells act by releasing a wide array of cytokines and 
expressing cell surface molecules such as CD40L that interact with other 
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cells. Functional CTL respond to and kill infected cells by secreting 
cytokines and cytotoxic molecules. The T cell-mediated immune 
responses are crucial for protection against obligately intracellular 
pathogens such as chlamydia. Intranasal challenge of athymic, T cell-
deficient nude mice with C. pneumoniae resulted in a prolonged infection 
that was not cleared from the lungs during the observation period of 5 
months (Vuola, 1999). To determine more precisely the role of different 
αβ T cells in protection of chlamydial infections, several strategies have 
been used, including genetically modified mice, in vivo depletion of a 
certain T cell population and adoptive transfer studies. The current view is 
that both CD4+ and CD8+ T cell responses, primarily through the 
secretion of IFN-γ, are required for the optimal anti-chlamydial immunity. 
CD4+ T cells not only secrete protective cytokines in response to 
chlamydia but also are required for the optimal stimulation of CD8+ T 
cells and B cells. The requirement of T cell response against chlamydial 
infections in humans has also been confirmed recently (Cohen et al.,
2000; Kelly, 2003).
A small group of T cells expresses receptors made up of γ and δ chains. γδ
T cells are relatively enriched in the epithelial tissues, especially in mice, 
and often show less TcR variability. A number of biologic activities 
characteristic of αβ T cells has also been described to γδ T cells, 
including secretion of cytokines and lysis of infected or malignant cells. 
However, biological functions of γδ T cells and the antigens they 
recognize are poorly understood. Recent evidence supports both an 
effector and regulatory role for γδ T cells in immune response against 
several infectious conditions (reviewed by Jameson et al., 2003). The 
protective role of γδ T cells has not been actively studied in C. 
pneumoniae infection. In psittacosis γδ T cells accumulate in the 
bronchoalveolar lavage and may play a role in the protection from lung 
injury caused by C. psittaci (Watanabe et al., 2000) In the clearance of 
pulmonary infection with C. trachomatis (MoPn) γδ T cells seem to play 
an ancillary role in regulating the αβ T cell response (Yang et al., 1998b). 
2.2.4.1. CD4+ T lymphocytes 
Naive CD4+ T cells differentiate into distinct subsets in response to 
antigen, costimulators and cytokines. The best defined subsets of CD4+ 
helper lineage are Th1 and Th2 cells which are distinguished most clearly 
by the cytokines they produce; IFN-γ is the signature cytokine of Th1 
cells, and IL-4 and IL-5 are the main cytokines of Th2 cells (Mosmann et
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al., 1989). Th1 cells promote cell-mediated effector responses and Th2 
cells influence B cell development and stimulate humoral responses such 
as the secretion of antibodies, predominantly of IgE. Both types of Th 
cells influence each other by the cytokines they secrete. 
Findings in animal models have established that a Th1-biased response 
with high IFN-γ level is most likely important for immunity against both 
C. trachomatis (Perry et al., 1997; Igietseme et al., 1998; Lampe et al.,
1998) and C. pneumoniae (Penttilä et al., 1998; Vuola et al., 2000; 
Rottenberg et al., 2002). Early after a C. pneumoniae infection, a mutant 
mouse strain without CD4+ T cells (CD4-/-) showed similar levels of 
bacteria in lungs compared to the wild type mice (Rottenberg et al.,
1999). However, during late infection or reinfection, CD4+ T cells control 
the bacterial growth as indicated by a higher number of bacteria in the 
lungs of double knock-out mice (CD4-/-/CD8-/-) compared with the level 
in single mutant mice (CD8-/- mice or CD4-/- mice). The depletion of 
CD4+ T cells by anti-CD4 antibodies during C. pneumoniae infection did 
not change the infection kinetics either in primary infection or reinfection 
(Penttilä et al., 1999). CD4+ T cells produce IFN-γ in response to C. 
pneumoniae infection, and play probably a complementary role in 
producing protective levels of this cytokine (Rottenberg et al., 2002; 
Rothfuchs et al., 2004). Recently first C. pneumoniae-derived antigens 
recognized by CD4+ T cells have been identified in a mouse model 
(Mygind et al., 2004). Recognition of polymorphic membrane proteins 
(Pmp) by murine CD4+ lymphocytes agrees with the observation that C.
pneumoniae COMC antigens are recognized by human T cells (Halme et
al., 1997). 
Some differences are apparent when comparing data obtained from C.
pneumoniae studies with data from C. trachomatis studies. The use of 
adoptive transfer and antibody-mediated in vivo depletion have clearly 
identified CD4+ T cells as the main population of cells required for the 
resolution of the genital tract infection in experimental models of C. 
trachomatis MoPn infection (Su et al., 1995, Perry et al., 1997). In vivo 
depletion of CD4+ T cells, but not CD8+ T cells, in immune B cell-
deficient mice altered the course of the genital tract infection, and CD4-
depleted mice were unable to resolve the C. trachomatis MoPn reinfection 
(Morrison S. et al., 2000). A number of C. trachomatis antigens which 
can be recognized by both mouse (Beatty et al., 1992) and human CD4+ 
T cells have been identified, including MOMP (Kim et al., 2001), Omp2 
(Goodall et al., 2001), Hsp60 (Deane et al., 1997), and several epitopes 
have been mapped within these antigens.
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2.2.4.2. CD8+ T lymphocytes 
Cytotoxic CD8+ lymphocytes (CTL) are critical for the protection against 
intracellular pathogens and malignant cells but also play a role in 
autoimmunity and transplant rejection. Effector CTL secrete cytokines, 
and exocytose lytic granules which deliver cytotoxic molecules directly 
into the target cell, resulting in apoptosis. CTL have two basic 
mechanisms by which to induce apoptosis, the receptor-mediated 
mechanism and the granule-based mechanism (reviewed by Russell et al.,
2002) (Figure 3).
The first pathway involves the engagement of the death receptor ligand 
(FasL) on the CTL and target cell death cell receptor (Fas), which results 
in classical caspase dependent apoptosis. The main function of this 
receptor mediated pathway is to eliminate self-reactive lymphocytes and 
thus prevent autoimmunity (van Parijs et al., 1996). In the granule-
exocytosis pathway a membrane disrupting protein known as perforin, 
and a family of serine proteases (granzymes) are secreted by exocytosis 
and they induce target cell apoptosis cooperatively either by caspase 
dependent or independent mechanisms (Trapani et al., 1998). Although 
perforin has an essential role in granzyme-mediated apoptosis, there is 
virtually no evidence of formation of transmembrane perforin-pores in the 
target cell in vivo, and uptake of the granzymes into the cells does not 
require perforin. It has been suggested that inside the target cell, perforin 
might enable granzymes to escape from the endosomal compartment into 
the cytoplasm enabling interaction with apoptotic substrates (reviewed by 
Trapani et al., 2002). Granzyme B signalling occurs via proapoptotic 
protein Bid; cleaved Bid translocates to the mitochondria and induces 
release of other proapoptotic proteins such as Bak and Bax, which then 
permits full activation of caspases and cell death (Wowk et al., 2004). The 
precise mechanisms of caspase-independent pathway and biological 
functions of other granzymes and molecules within the granules are still 
unclear. Current evidence suggests that the perforin/granzyme pathway is 
not a single pathway but a series of parallel pathways depending on the 
spectrum of granzymes expressed in a given situation (Russell et al.,
2002). CTL avoid self-destruction by secreting cathepsin B which binds 
to their surface after degranulation and inactivates the perforin molecules 
(Balaji et al., 2002). This perforin/granzyme pathway is involved in 
defence against intracellular pathogens. One potential limitation of the 
mouse model for addressing the importance of the CD8+ T cells in the 
control of infection is that mice lack a granule-associated protein, 
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granulysin, which can kill a broad spectrum of pathogenic bacteria such 
as intracellular mycobacteria (Clayberger et al., 2003). 
Figure 3. Currently identified pathways of Fas receptor and granzyme B-
induced apoptosis. FADD, Fas-associated protein with death domain. Bid 
(BH3-interacting domain death agonist), Bax (Bcl-2-assciated X protein), 
Bak (Bcl-2 homologous antagonist killer), proapoptotic proteins. Apaf-1, 
apoptotic protease activating factor-1. iCAD, inhibitor of caspase 
activated DNase. CAD, caspase activated DNase. Adapted from Russell 
et al., 2002. 
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Since chlamydia replicates within a vacuole, it was initially thought that 
in the absence of cytosolic proteins derived from the bacteria, CD8+ T 
cells have no role in protection. However, chlamydial proteins are able to 
elicit CD8+ T cell responses and chlamydia-specific CD8+ T cells can be 
isolated following infection. The precise route by which chlamydial 
antigens are presented to CD8+ T cells is not well-defined. The protective 
role of CD8+ cells in immunity against C. pneumoniae has been shown by 
the enhanced severity of infection of genetically modified mice without 
CD8+ T cells. After C. pneumoniae challenge, 10-fold higher numbers of 
IFU are detected in the lungs of CD8-/- mice than those of wild type mice 
(Rottenberg et al., 1999). Enhanced susceptibility to C. pneumoniae
infection has also been shown in TAP-1/β2-microglobulin mutant mice 
which are deficient in antigen presentation, surface class I molecules and 
CD8+ T cells (Rottenberg et al., 1999). In spite of delayed kinetics and 
higher numbers of IFU in lungs, CD8-knockout mice are able to eliminate 
primary infection, and during reinfection, no significant differences can 
be observed between CD8-/- and immunocompetent mice. Similarly, 
depletion of CD8+ T cells by anti-CD8 antibodies causes impairment in 
clearance of primary infection in BALB/c mice (Penttilä et al., 1999). The 
latter technique, depletion of CD8+ T cell by antibodies, is an effective 
method for studying acquired immunity because natural immunity is 
allowed to form during the primary infection after which a certain cell 
type can be depleted specifically. In contrast to CD8-knockout mice, 
CD8-depleted mice have a worse course of reinfection, numbers of IFU 
from lungs are higher than the levels in reinfected immunocompetent 
mice, and the kinetics of reinfection resembles the kinetics of wild type 
mice during primary infection (Penttilä et al., 1999). According to this 
data, acquired immunity is at least partially CD8-dependent. To date a 
number of CD8 epitopes within the C. pneumoniae antigens have been 
identified and the peptide-specific CD8+ T cells have been shown to 
control the chlamydial growth in vitro (Wizel et al., 2002).  A recent 
report provides additional evidence that the specific CD8+ T cell response 
induced by a CD8 epitope vaccine protects from C. pneumoniae infection 
in vivo (Pinchuck et al., 2005). However, the protective effector 
mechanisms of CD8+ T cells in chlamydia immunity in vivo are not well-
known. CD8+ T cells can respond both by secreting cytokines such as 
IFN-γ and TNF-α and by directly lysing infected cells. Since perforin-
deficient mice have a normal course of C. pneumoniae primary infection, 
it seems that cytokines, especially IFN-γ, are the main factors of CD8+ T 
cells that down-modulate the infection at least after the first challenge 
(Rottenberg et al., 1999). Whether perforin is involved in defence against 
C. pneumoniae reinfection remains to be studied. 
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The importance of CD8+ T cells in protection against C. trachomatis has 
been equivocal because of discrepant results obtained from in vitro and in 
vivo experiments. CD8+ T lymphocytes are detected at the site of C. 
trachomatis infection where they are likely to contribute to protection 
(Igietseme et al., 1994; Starnbach et al., 1994; Loomis et al., 2002). 
However, CD8-deficient mice (β2m-/-) but not CD4-deficient mice (class 
II-/-) are able to resolve a C. trachomatis MoPn genital tract infection 
(Morrison et al., 1995). Additionally, in vivo depletion of CD8+ T cells 
has no effect on C. trachomatis MoPn reinfection in B cell-deficient mice 
(Morrison S. et al., 2000) indicating only minor participation of CD8+ T 
cells in protection against C. trachomatis MoPn infection. On the 
contrary, adoptive transfer of C. trachomatis LGV-specific CD8+ T cells 
into mice mediates protection from intravenous challenge. This protection 
is dependent on IFN-γ production (Lampe et al., 1998). Recently two C.
trachomatis-derived antigens that are recognized by murine CD8+ T cells 
were identified; Cap1 (Fling et al., 2001) and CrpA (Starnbach et al.,
2003). Both of these antigens are probably associated with the inclusion 
membrane. By using synthetic peptides from C. trachomatis MOMP, 
Omp2 and Hsp60 proteins, human CD8+ T cells can be isolated from 
infected individuals (Holland et al., 1997; Kim et al., 2000; Gervassi et
al., 2004). Active trachoma with C. trachomatis infection has been 
associated with an increased expression of IFN-γ, IL-12p40, and perforin 
in a population where trachoma is endemic. The expression of perforin is 
used as a marker for CTL activity (Burton et al., 2004). 
Chlamydiae may hide from T cells by down-regulating the processing and 
presentation of its own antigens in the host cell. Reduced MHC class I 
expression in chlamydia infected cell cultures is linked to IL-10 
production induced by C. pneumoniae infection (Caspar-Bauguil et al.,
2000). In addition to the inhibitory effect on MHC class I mediated 
presentation, IL-10 is also known to be involved in  switching the immune 
response from Th1 to Th2 by suppressing the Th1 type cytokine 
production (McGuirk et al., 2002), and this might contribute to 
chlamydial escape from the immune system. Moreover, chlamydiae 
secrete a chlamydial protease, CPAF which degrades the host cell 
transcription factor (RFX-5) essential for expression of MHC class I and 
II molecules (Zhong et al., 2001; Dong et al., 2005). Dimeric CPAF 
consist of 35 kDa CPAFc and 29 kDa CPAFn fragments that are 
associated with each other and both contribute to CPAF activity (Shaw A. 
et al., 2002).  CPAF has a very slow turnover in the host cytoplasm, 
indicating that it inhibits antigen presentation without being presented 
itself. The translocation of CPAF into the host cell cytoplasm appears to 
be fully active during acute infection but is fully or partially inhibited 
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during persistent infection in epithelial HEp-2 cells (Heuer et al., 2003). 
The mechanism of CPAF translocation is not known, but is reported to be 
TTSS-independent (Dautry-Varsat et al., 2004). Recently, CPAF 
synthesis and high anti-CPAF antibody production were detected during a 
C. trachomatis infection in man suggesting that CPAF is also produced 
and immunogenic in humans (Sharma et al., 2004). The presence of 
CPAF in environmental chlamydiae (Collingro et al., 2005) which grow 
in hosts that do not possess the MHC system, indicates that the protease 
has a different function in lower eukaryotic hosts.
2.2.5. IFN-γ
Chlamydial infection generates a cytokine response by interacting with 
the epithelia or with cells of the immune system. The cytokine network 
initiates the inflammation and largely determines the outcome of infection 
and disease. C. pneumoniae infected cells produce a number of cytokines, 
including proinflammatory cytokines TNF-α, IL-1β and IL-6 
(Kaukoranta-Tolvanen et al., 1996). C. pneumoniae infection also induces 
an IFN-γ response in infected mice (Penttilä et al., 1998). Although 
dissimilar sensitivities to IFN-γ have been registered in different 
chlamydial strains, IFN-γ appears to be a key effector cytokine restricting 
C. pneumoniae infections in mouse models, as demonstrated by the 
enhanced bacterial levels in mice that lack an IFN-γ receptor (IFN-γR-/-)
(Rottenberg et al., 1999), and in mice treated with neutralizing anti-IFN-γ
antibodies (Vuola et al., 2000), compared with controls. IFN-γ is secreted 
by the cells of both the innate and acquired immune systems. By using the 
T, B, NK and IFN-γ-deficient mice C. pneumoniae infection has been 
shown to be controlled by macrophages, Th1 cells and CD8+ T cells 
through their ability to secrete IFN-γ (Rothfuchs et al., 2004). In fact, the 
impairment of a C. pneumoniae infection in CD8-knockout mice was 
associated with an altered cytokine balance as indicated by increased Th2 
cytokines (IL-4, IL-10) and delayed IFN-γ production (Rottenberg et al.,
1999). IFN-γ induces the synthesis of the host enzyme indoleamine-2,3-
deoxygenase (IDO), which degrades L-tryptophan to N-kynurenine 
thereby limiting tryptophan availability. Since many chlamydial species 
and serovars are not capable of synthesizing enough of their own 
tryptophan, chlamydial replication is inhibited by IFN-γ treatment (Byrne 
et al., 1986; Morrison R., 2000). IFN-γ may also control the chlamydial 
infections by enhancing the bactericidal mechanisms of macrophages, 
facilitating antigen presentation and Th1 polarization of the immune 
response (reviewed by Rottenberg et al., 2002). On the other hand, 
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treatment of chlamydia-infected HeLa cells with IFN-γ results in the 
development of persistent infection characterized by the formation of 
aberrant but viable forms of the organism (Beatty et al., 1993). Cells that 
contain the aberrant vacuoles seem to be more resistant to apoptosis 
(Perfettini et al., 2002). Delayed development of chlamydia and persistent 
infection are associated with immunopathology and more severe outcome 
of disease. The role of the IDO pathway in protection and persistence in 
vivo remains to be clarified. However, mice can resolve chlamydial 
infections in the absence of IFN-γ suggesting that there is also IFN-γ-
independent mechanism involved in protection (Vuola et al., 2000).
2.2.6. Vaccination against C. pneumoniae infection 
Although chlamydial infections can be treated with antibiotics such as 
tetracycline derivatives, doxycycline and macrolides and azalides 
including erythromycin and azithromyzin, vaccination is considered to be 
the most desirable defence against chlamydial diseases. However,
induction of robust and long-lasting cell-mediated immune response 
against intracellular pathogens is an ongoing and difficult challenge in 
vaccine development. Live vaccines elicit such responses, but in many 
cases cannot yet be safely used in humans, especially in 
immunocompromised individuals. In early human trials, a whole 
inactivated C. trachomatis agent as a vaccine reduced incidence of 
trachoma but led to more severe disease after subsequent challenge, 
probably due to exacerbated immunopathology (Grayston et al., 1978). 
To avoid the unwanted adverse effects, well-defined subunit vaccines are 
intensively studied, and a current view is that effective immunization can 
probably be achieved by combinations of several chlamydial antigens 
(Igietseme et al., 2003). After decoding the genomic sequence of 
chlamydiae, systematic screening approaches and genome-based 
applications for the identification of new antigens have become available 
(Knaust et al., 2004). The focus on subunit vaccines also requires the 
development of novel and effective vectors, and adjuvant systems. 
DNA vaccines encoding proteins from pathogens facilitate the 
presentation of antigen on MHC molecules, and the induction of cell-
mediated immunity. Furthermore, methylated CpG motifs of the 
backbone plasmid elicit a cytokine response that supports the induction of 
an immune response (reviewed by Klinman et al., 2004). Immunizations 
with a DNA encoding chlamydial antigen have been promising. Delivery 
of chlamydial MOMP, Omp2, Hsp60, and ADP/ATP translocase with 
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DNA induce partial protection against C. pneumoniae lung infection 
(Murdin et al., 2000; Penttilä et al., 2000; Bandholtz et al., 2002). The 
DNA-based immunization strategy has been highly effective in mice, 
while it is less immunogenic in humans and other primates. Immune 
responses primed by DNA vaccines can be amplified by a protein antigen 
boost, or by combining DNA and viral vectors (Doria-Rose et al., 2003). 
Recombinant proteins as vaccines are well-defined and easily applied to 
large-scale production. Professional APC such as dendritic cells can 
process endocytosed exogenous antigens by the cytosolic pathway and 
present the epitopes in the context of MHC class I molecule (Rodriguez et 
al., 1999). Most importantly, recent studies show that the endosomal 
processing of an antigen generates a repertoire of epitopes well 
overlapping the epitopes generated by the cytosolic pathway (Cho et al.,
2003). Consequently, CD8+ T cells induced by an endocytosed 
immunogen are able to recognize epitopes generated by the cytosolic 
pathway after natural infection. This is a crucial point for vaccine 
development that aims at the priming of cell-mediated immunity by 
protein antigens. Genomic and proteomic studies make new information 
and new vaccine candidates available. Five chlamydial recombinant 
protein antigens (CopN, Pmp2, Pmp10, OmpH-like, and enolase) are able 
to induce protective immunity against C. pneumoniae spleen infection in 
hamsters challenged intraperitoneally (Sambri et al., 2004; Finco et al.,
2005). In order to assess the value of these antigens as vaccines, their 
protective capacity needs to be studied in a mouse model of a C.
pneumoniae lung infection that resembles more the natural infection in 
humans.  
The knowledge of the MHC motifs has been used to predict potential 
epitopes within the primary sequence of a pathogen-derived protein. The 
main benefit of the epitope-based vaccine is the ability to immunize with 
a minimal structure stimulating an effective immune response without 
undesirable side-effects. However, the design of a T cell epitope vaccine 
is often complicated by the polymorphism of human MHC proteins, and a 
single epitope will probably not be effective in the general population. 
This can be overcome by the use of vaccines comprising several peptides, 
which would be effective in various populations. Furthermore, it is 
possible to select epitopes restricted to HLA which are most frequent in 
the population of interest. Since the immunogenicity of synthetic peptides 
is often low, an appropriate carrier or adjuvant is usually employed in 
their elaboration into a vaccine. 
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2.3. ANTIGEN PRESENTATION BY MAJOR 
HISTOCOMPATIBILITY COMPLEX, MHC  
Although chlamydiae reside strictly within the inclusion, chlamydia-
specific CD4+ T cells and CD8+ T cells can be isolated from infected 
mice (Starnbach et al., 1994; Su et al., 1995a) and humans (Gervassi et
al., 2004; Steele et al., 2004). T cells recognize the antigenic peptides in 
the context of MHC class I and class II molecules at the surface of 
infected cells or APC. The efficiency of the peptide presentation by MHC 
is dependent on the extreme polymorphism in the MHC-encoding loci. 
The mouse MHC includes classical MHC class I (MHC-Ia) that 
comprises the H2-D, H2-K and H2-L subclasses, and classical MHC class 
II (MHC-IIa) that comprises H2-A, H2-E and H2-P subclasses. Other 
MHC include nonclassical MHC-I (MHC-Ib) that comprises the H2-Q, 
H2-M and H2-T subclasses and the nonclassical MHC-II (MHC-IIb) that 
comprises H2-DM and H2-DO subclasses. Human leukocyte antigen 
(HLA) sequence database of the international ImMunoGeneTics (IMGT) 
currently contains 349 HLA-A, 626 HLA-B, 182 HLA-C, 5 HLA-E, 2 
HLA-F, and 15 HLA-G class I alleles. In addition, 3 HLA-DRA, 470 
HLA-DRB, 28 HLA-DQA1, 60 HLA-DQB1, 22 HLA-DPA1, 116 HLA-
DPB1, 4 HLA-DMA, 6 HLA-DMB, 8 HLA-DOA and 8 HLA-DOB class 
II alleles have been named (http://www.ebi.ac.uk/imgt/hla/). 
Immunodominant determinants among a number of fragmented peptides 
produced in the antigen processing steps are selectively bound by these 
different MHC molecules. Differences in assembly, intracellular transport 
and usage of chaperones allow MHC class I and II molecules to present 
peptides from different intracellular compartments and thereby from 
different sources.
2.3.1. MHC class II antigen presentation 
Antigen processing is thought to be a key determinant of the quality and 
quantity of a CD4+ T cell response. Professional APC capture and 
internalize exogenous protein antigens into endosomes where several 
types of proteases, notably cathepsins, degrade proteins and generate 
peptides for the class II pathway. The α and β chains of class II molecules 
are co-ordinately synthesized and associate with each other in the 
endoplasmic reticulum (ER). The nonpolymorphic invariant chain (Ii) is 
engaged to the peptide binding cleft of the heterodimer. As a result class 
II MHC molecules cannot bind and present peptides they encounter in the 
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ER. The Ii also promotes the assembly of a class II molecule and directs it 
to the endosomal vesicles. In class II rich endosomes, called the MHC 
class II compartments (MIICs) proteolytic enzymes degrade Ii and leave 
only a short remnant called class II associated invariant chain peptide 
(CLIP) lodged in the peptide-binding cleft. Removal of CLIP is 
accomplished by the action of HLA-DM (H-2M in the mouse) molecule. 
Once CLIP is removed, processed peptides are able to bind class II MHC 
molecules stabilizing the complex. MHC II molecules display peptides of 
variable length, the optimal length being 12 to 16 residues. Selective 
traffic delivers the peptide-class II complexes to the surface of APC 
whereas the other molecules involved in antigen presentation stay in the 
vesicle. On the cell surface peptide-MHC class II complexes are long 
lived and allow interactions with antigen-specific CD4+ T cells. An 
alternative minor pathway also exists, in which cell surface MHC II 
molecules are recycled into endosomes and loaded with peptides in an Ii 
and DM-independent manner (Sinnathamby et al., 2003).
2.3.2. Conventional MHC class I antigen presentation 
In general, MHC class I molecules present peptides derived from 
endogenous antigens. Cytosolic or nuclear antigens are targeted for 
degradation by conjugation with ubiquitin and subsequently degraded into 
small peptides by proteasome (Jentsch, 1992; Roos-Mattjus et al., 2004). 
IFN-γ induces the expression of proteasome subunits LMP2 and LMP7 
(low-molecular mass polypeptide), and this may influence the specificity 
of proteasome cleavage and favour peptides suited to the MHC class I 
molecules (Schmidtke et al., 1998; Kessler et al., 2002; Kloetzel et al.,
2004). After degradation, the peptides are translocated into the ER lumen 
by a transporter associated with antigen processing (TAP). The size of the 
peptide and its sequence affects the efficiency of translocation by TAP 
(Momburg et al., 1994; Peters et al., 2003). In the ER, chaperone-assisted 
assembly generates a stable heterodimeric complex containing MHC class 
I heavy chain, β2-microglobulin and a peptide. The binding of peptide to 
the MHC I molecule is related to the structure of the peptide binding 
groove in a class I heavy chain. These peptide binding pockets vary in 
depth and chemical nature between allelic variants of MHC I molecule 
and thus determine the set of peptides that can be bound by certain allele 
(Rammensee et al., 1999). Class I molecules can accommodate peptides 
that are 8 to 11 residues long, and it has been calculated that only 1 
peptide is binding to an MHC class I molecule from 104 proteins degraded 
(Yewdell, 2001). Upon peptide binding, the stable MHC class I complex 
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is transported to the cell surface via the constitutive secretary pathway. 
Consequently, various factors are implicated in the epitope selection: 
antigen processing by the proteasome, TAP-dependent peptide transport, 
affinity of the peptide for the MHC molecules, the transport of 
MHC/peptide complexes to the cell surface, and the TcR repertoire.  
2.3.3. Alternative MHC class I antigen presentation 
Although the major route for presentation by MHC I molecules is the 
conventional pathway described above, a variety of exogenous proteins 
can also be presented by MHC I molecule, and there are well-documented 
alternative ways for class I peptide loading. One involves the release of 
antigens or peptides from the phagosome to the cytosol and their access to 
the conventional proteasome-dependent pathway, and another involves 
unusual post-golgi loading of MHC I molecules (Grommé et al., 2002; 
Schirmbeck et al., 2002). In addition, the recent discovery of the fusion of 
the ER membrane with the phagosome provides a new potential 
mechanism to load MHC I molecules (Ackerman et al., 2004). The ability 
to present exogenous antigens by MHC I molecules seems to be a feature 
of particular professional APC such as DC, and may be highly relevant in 
the cross-priming process. These alternative pathways have become of 
even more interesting with the discovery that naked DNA can be used as 
an effective vaccine, generating both CD4+ and CD8+ T cell responses.
C. trachomatis–specific CD8+ T cell clones have been shown to 
recognize chlamydial antigens processed via the conventional class I 
processing pathway, because the CTL responses were blocked by 
treatment of infected APC with proteasomal inhibitors such as lactacystin 
and trileucine peptide vinyl sulfone, and Golgi inhibitor brefeldin A 
(Gervassi et al., 2004; Steele et al., 2004). Correspondingly, the treatment 
of C. trachomatis-infected DC and macrophages with bafilomycin A1 that 
prevents the acidification of the endosomal compartment and the 
exogenous antigen processing pathway failed to block the recognition and 
CTL response (Steele et al., 2004). 
3.3.4. Nonclassical class I molecules 
Nonclassical class I molecules (class Ib) are structurally related to 
classical class I molecules (class Ia), but they display considerably less 
polymorphism and present a more limited range of ligands than the class 
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Ia molecules. In mice, the class Ib genes map to three defined regions, the
Q, T, and M regions, adjacent to the H-2 complex encoding the class Ia 
molecules. In humans, HLA-E, HLA-F, and HLA-G are three identified 
MHC-linked human class Ib genes. 
CD1 molecules are a set of nonclassical class I molecules encoded outside 
the MHC. CD1 bind to β2-microglobulin but, in contrast to MHC I, are 
able to present lipid antigens to CD1-restricted T cells (found among 
CD4+, CD8+, double negative and γδ T cell subsets). CD1 molecules are 
expressed on professional APC and epithelia, and they engage ligands in 
the endocytic pathway. CD1 proteins diversify the range of epitopes in 
pathogens that the immune system is able to recognize. The CD1 genes 
are a distinct locus of tightly clustered genes located in chromosome 1 in 
humans and in chromosome 3 in mice, regions that are unlinked to the 
MHC genes. The five CD1 genes have been identified in man, 
corresponding to five CD1 proteins. Mice only contain two highly 
homologous CD1d genes. CD1a-c and CD1e are recognized by 
conventional αβ T cell receptors, whereas CD1d is recognized by a 
specific subset of cells called natural killer T cells (NKT) cells. A CD1-
mediated lipid presentation to natural killer (NK) T cells is highly 
conserved between rodents and humans suggesting that these class I 
molecules might be performing some ancient and highly conserved 
function (Kronenberg et al., 1999). In addition to antimicrobial immunity, 
CD1-reactive T cells contribute to antitumor immunity, autoimmunity and 
the regulation of tolerance (reviewed in Brigl et al., 2004). The potential 
limitation of murine models for studying nonclassically restricted 
responses is that mice lack group 1 CD1 molecules (CD1a-CD1c and 
CD1e).
Class Ib-restricted CD8+ T cells have been found to be an important 
component of the T cell response to several intracellular pathogens such 
as Listeria, Salmonella, and Mycobacterium (Soloski et al., 2000). The 
contribution of nonclassically restricted CD8+ T cells to chlamydial 
immunity has not been investigated in detail. By using C. trachomatis 
infected DC as stimulators both class Ia-restricted and nonclassically 
restricted CD8+ T cells were isolated from currently infected individuals 
(Gervassi et al., 2003). 
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3. AIMS OF THE STUDY 
The overall objective of this thesis was the identification of mechanisms 
for the targeted induction of protective cytotoxic T lymphocyte-mediated 
immunity against C. pneumoniae infection in vivo, and thereby 
establishing general rules for a vaccination strategy based on the CD8+ T 
cell response.
The principal goals of this study were: 
• Establishment of a strategy for the identification of functional 
CD8 epitopes in mouse models. Identification of mouse and 
human CD8 epitopes from C. pneumoniae proteins. 
• Characterization of C. pneumoniae infection and immune 
responses in HLA-A2.1 transgenic mice.  
• Evaluation of various immunization strategies (DNA, rSFV, heat-
treated protein antigen) allowing effective presentation of the 
identified CD8 epitopes, and induction of protection against C. 
pneumoniae challenge.
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4. MATERIALS AND METHODS 
The bacterial strain, cell lines and mouse strains used in this study are 
listed in Table 1. The plasmids and recombinant constructs are listed in 
Table 2. The materials and methods used in this study are described in 
detail in the indicated articles and are summarized in Table 3. 
Table 1. Bacterial strain, cell lines and mouse strains used in this study. 
Bacterial strain Description Article Reference 
C. pneumoniae K6 C. pneumoniae isolate Kajaani 6 I, II, III, 
IV
Prof. P. Saikku, 
University of Oulu 
Ekman et al., 1993 
Cell lines 
P815 H-2d, a mouse mastocytoma cell 
line 
I, III ATCC number 
TIB-64 
BALB/3T3 H-2d, a BALB/c mouse embryo 
(fibroblast) cell line 
I ATCC number 
CCL-163 
RMA H-2b, a T cell lymphoma cell 
line derived from the Rauscher 
murine leukemia virus-induced 
RBL-5 cell line 
I Ljunggren et al., 
1985 
RMA-S H-2b, a TAP-deficient T cell 
lymphoma cell line 
I
1308.1 H-2b, a thymic stromal cell line I Faas et al., 1993 
HL A human epithelial cell line I, II, III, 
IV
Cles et al., 1990 
BHK-21 A hamster kidney cell line III ATCC number 
CCL-10 
T2 A human lymphoblastic cell line 
expressing HLA-A2 
II ATCC number 
CRL-1991 
Mouse strains*    
BALB/c H-2d I, III, IV Harland Nederland, 
Horst, The 
Netherlands. 
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C57BL/6 H-2b I, II Harland Nederland, 
Horst, The 
Netherlands. 
HHD ?2-microglobulin HLA-A2.1 
monochain transgenic H-2Db
?2m double knockout mice 
II The founder mice 
were provided by 
Dr. Lemonnier 
from Pasteur 
Institute, France 
(Firat et al., 1999) 
Pascolo et al., 1997 
*) All animal studies were approved by the institutional animal care and use committee, 
and the provincial board. 
Table 2. Plasmids and recombinant constructs used in this study 
Plasmid / 
recombinant
construct Description Article Reference 
pcDNA Eukaryotic expression vector III Invitrogen®
pmomp pcDNA3.1 having C. pneumoniae
MOMP encoding insert at Bg1II 
III Penttilä et al., 
2000 
pomp2 pcDNA3.1 having C. pneumoniae
Omp2 encoding insert at BamHI 
III Penttilä et al., 
2000 
phsp60 pcDNA3.1 having C. pneumoniae
Hsp60 encoding insert at EcoRI 
III Penttilä et al., 
2000 
pSFV4.2 Expression vector III Prof. P. 
Liljeström, 
Karolinska 
Institutet (KI) 
pSFV/lacZ pSFV4.2 having E. coli ?gal 
encoding insert 
III Prof. 
Liljeström, KI 
pSFV/momp pSFV4.2 having C. pneumoniae
MOMP encoding insert at BamHI 
III Prof. 
Liljeström, KI 
III 
pSFV/omp2 pSFV4.2 having C. pneumoniae
Omp2 encoding insert at BamHI 
III Prof. 
Liljeström, KI 
III 
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Table 3. Methods used in this study 
Method Described and used in 
Culture conditions 
C. pneumoniae 
Cell lines 
CTL lines 
I, II, III, IV 
I, II, III, IV 
I, II, III 
Infection 
Cell lines in vitro 
Mice in vivo 
I, II 
II, III, IV 
Peptide prediction I, II 
Peptide-binding assay I, II 
Immunization 
DNA / SFV 
Epitopes 
Heat-aggregated antigens 
III 
II
IV
Isolation and maintenance of CTL lines I, II, III 
Cytotoxicity assay I, II, III 
Proliferation assay I, II, III, IV 
Cytokine assay I, II, III, IV 
Flow cytometric assay I, II, III, IV 
Expression recombinant proteins in 
eukaryotic cells 
III 
Serology II, III, IV 
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5. RESULTS AND DISCUSSION 
5.1. Identification of C. pneumoniae-derived CD8 epitopes 
Instead of responding to all possible peptides within a complex antigen, 
the CD8+ T cell response is directed against a few immunogenic 
determinants. By using computer based algorithms, peptide segments that 
are likely to bind to the MHC class I molecules can be predicted from the
amino acid sequence of a chosen antigen. The highest prediction scores 
are given to peptide sequences which fit best to the anchor residues of a 
given MHC motif. Potential peptides can be synthesized and tested for 
their ability to activate cytotoxic T lymphocytes (CTL) in vivo. 
5.1.1. Peptide prediction from C. pneumoniae proteins 
The genomic sequence data of C. pneumoniae (GenBank accession 
number AE001363) and the knowledge of the motifs for MHC class I 
alleles H-2d and H-2b (Rammensee et al., 1999; www.syfpeithi.de) were 
used to predict potential CD8 epitopes from four C. pneumoniae proteins: 
the MOMP, Omp2, Pomp5, and Hsp60. Out of hundreds of peptide 
sequences 53 peptides with the highest prediction score were selected and 
synthesized by applying 9-fluorenylmethoxy carbonyl chemistry (Table 
4). The identity of the peptides was confirmed by mass spectroscopy 
analysis, and the purity of the peptides (>80%) was assured by high 
performance liquid chromatography (HPLC) purification. Previously 
described CTL epitopes from ovalbumin (Rotzschke et al., 1991) and 
Escherichia coli ?-galactosidase (Gavin et al., 1993) were used as 
controls for induction and stimulation of CTL lines. 
The MHC-binding capacities of the synthetic H-2b peptides were 
evaluated in vitro by an MHC class I stabilization assay before the 
immunizations. 71% (17/24) of the H-2b peptides were clearly able to 
bind to and stabilize the MHC I molecules at the surface of a TAP-
deficient RMA-S cell line (Table 4). Peptides with high prediction scores 
are assumed to bind efficiently to MHC I molecule in vitro, and this 
turned out to be true in case of many peptides. However, the prediction 
score does not always correlate with the experimentally determined 
binding activity of the peptide. For example, a Pomp5-derived peptide 
9162, showing a high prediction score (25), did not bind to MHC I 
molecules in the stabilization assay (-). This may be due to the fact that all 
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parameters affecting the binding of a given peptide, such as three-
dimensional structural parameters, are not included in the prediction 
pattern. The peptides possessing H-2d-binding motif were used for 
immunizations without performing the binding assay because a TAP-
deficient H-2d cell line was not available to us. 
5.1.2. CTL response induced by synthetic peptides 
To determine the immunogenicity of predicted peptides empirically, 53 
synthetic peptides (19 from the MOMP, 8 from the Omp2, 11 from the 
Pomp5, and 15 from the Hsp60) were tested for the ability to induce CTL 
response in mice. The mice were subcutaneously immunized with the 
different mixtures of peptides which were chosen so that the peptides did 
not compete for binding to the same MHC class I allele.  Upon peptide 
immunization the splenocytes were isolated and stimulated with the 
corresponding peptides in vitro, and the cytotoxic activity against peptide-
pulsed target cells was detected. 19 (36%) of all tested peptides were 
capable of inducing a CTL response in vivo, and long-term CTL lines 
were established against seven (13%) of the peptides. Two peptides from 
MOMP (7087, 7093), Omp2 (8482, 8511) and Hsp60 (7233, 7239), and 
one peptide from Pomp5 (9165) were recognized by these long-term 
peptide-specific CTL lines. 
In most cases, there is a positive correlation between binding to MHC and 
immunogenicity (Sette et al., 1994; Ressing et al., 1995). Two H-2b
peptides that induced CTL lines (7087 and 9165) were also able to 
strongly stabilize the MHC assembly in the binding assay. Peptide 7093 
bound to MHC I with a lower affinity but was still able to induce a CTL 
response. Immunogenicity of the peptides with lower binding activities 
might be explained by more efficient processing and presentation of these 
particular epitopes and/or the presence of specific CD8+ T cells with 
unusually high avidities which could compensate for the lower binding 
affinity. There were also peptides with good binding activity but 
incapable of eliciting any CTL response following peptide immunization 
suggesting that some T cell receptor specificities were lacking in CTL 
repertoire.
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Table 4. List of synthetic peptides used in immunizations. Bold peptides 
were capable of inducing CTL response after peptide immunization of 
mice. ND = not done. 
Protein Peptide name Sequence / position Bindingmotif 
Prediction 
score
Exp
binding
to MHC I 
CTL
response/
CTL line 
MOMP 6333 232 GYKGVAFPL 240 H-2Kd 27 ND No/No 
MOMP 6340 205 QYAQSKPKV 213 H-2Kd 23 ND No/No 
MOMP 7069 332 SFSDFMQI 339 H-2Kb 19 +/- No/No 
MOMP 7070 131 RFDVFCTL 138 H-2Kb 22 +/- No/No 
MOMP 7071 119 TNAGFIAL 126 H-2Kb 22 - No/No 
MOMP 7084 116 EWFTNAGFI 124 H-2Db 22 + Yes/No 
MOMP 7087  67 GDYVFDRI 74 H-2Kb 22 +++ Yes/Yes 
MOMP 7093  319 SLLGNATAL 327 H-2Db 27 + Yes/Yes 
MOMP 7097 149 STAFNLVGL 157 H-2Db 26 + Yes/No 
MOMP 7100 162 GTTVNANEL 170 H-2Db 24 +++ Yes/No 
MOMP 7101 173 VSLSNGVVEL 182 H-2Db 29 +++ Yes/No 
MOMP 7167 303 QPKLPTAVL 311 H-2Ld 22 ND No/No 
MOMP 7168 214 QSKPKVEEL 222 H-2Ld 21 ND Yes/No 
MOMP 7169 6 KSALLSAAF 14 H-2Ld 20 ND No/No 
MOMP 7170 190 WSVGARGAL 198 H-2Ld 20 ND Yes/No 
MOMP 7192 16 GSVGSLQAL 24 H-2Ld 20 ND No/No 
MOMP 7202 142 NGYIRGNST 150 H-2Dd 26 ND No/No 
MOMP 7203 305 KLPTAVLNL 313 H-2Dd 24 ND Yes/No 
MOMP 7205 146 RGNSTAFNL 154 H-2Dd 23 ND Yes/No 
Omp2 8474 6 ASCFASGGI 14 H-2Ld 16 ND No/No 
Omp2 8475 150 TTPTSDGKL 158 H-2Dd 21 ND No/No 
Omp2 8478 112 VGSPYPIEI 120 H-2Dd 18 ND No/No 
Omp2 8482  59 RGAFCDKEF 67 H-2Dd 18 ND Yes/Yes 
Omp2 8508 113 GSPYPIEIL 121 H-2Ld 20 ND No/No 
Omp2 8509 33 KPAPVPVTA 41 H-2Ld 14 ND No/No 
Omp2 8510 115 PYPIEILAI 123 H-2Kd 20 ND No/No 
Omp2 8511  85 CYGRLYSVKV 94 H-2Kd 18 ND Yes/Yes 
Pomp5 9125 893 SHYAFSPM  H-2Kb 24 + No/No 
Pomp5 9129 897 FSPMFEVL H-2Kb 23 ++ No/No 
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Pomp5 9149 367 AKITNLRAI  H-2Db 27 ++ No/No 
Pomp5 9152 793 TYAPYIKL H-2Kb 22 +/- No/No 
Pomp5 9154 1 MKSQFSWL H-2Kb 21 - No/No 
Pomp5 9156 538 QDFSFVQL H-2Kb 21 +/- No/No 
Pomp5 9157 593 LAWTNTGYL  H-2Db 26 ++ No/No 
Pomp5 9162 820 FDDSNLFNL H-2Db 25 - No/No 
Pomp5 9164 118 SLTGFSSL H-2Kb 22 ++ No/No 
Pomp5 9165  283 QAVANGGAI 291 H-2Db 25 +++ Yes/Yes 
Pomp5 9166 797 YIKLNLTYI H-2Db 24 ++ Yes/No 
Hsp60 7227  222 IYDKKISGI 230 H-2Kd 23 ND No/No 
Hsp60 7229 207 NPETQECVL 215 H-2Ld 21 ND No/No 
Hsp60 7232 357 TSDYDKEKL 365 H-2Ld 19 ND No/No 
Hsp60 7233  7 KYNEEARKKI 16 H-2Kd 24 ND Yes/Yes 
Hsp60 7235 486 AYTDMIDAGI 495 H-2Kd 20 ND Yes/No 
Hsp60 7236 198 GYLSSYFST 206 H-2Kd 19 ND No/No 
Hsp60 7237 507 ESARSIAGL 515 H-2Ld 21 ND No/No 
Hsp60 7238 31 LGPKGRHVVI 40 H-2Dd 23 ND Yes/No 
Hsp60 7239  32 GPKGRHVVI 40 H-2Ld 18 ND Yes/Yes 
Hsp60 7240 31 LGPKGRHVV 39 H-2Dd 23 ND No/No 
Hsp60 7241 281 FGDRRKAML 289 H-2Dd 27 ND No/No 
Hsp60 7242 87 DGTTTATVL 95 H-2Dd 22 ND No/No 
Hsp60 7243 297 GGQLVSEEL 305 H-2Dd 21 ND Yes/No 
Hsp60 7246 99 IYSEGLRNV 107 H-2Kd 19 ND Yes/No 
Hsp60 7247 411 ILPGGGTAL 419 H-2Kd 22 ND No/No 
OVA 7548 257 SIINFEKL 264 H-2Kb 25 +++ Yes/Yes 
?-Gal 9339 876 TPHPARIGL 884 H-2Ld 25 ND Yes/Yes 
The specificity of the isolated CTL lines was studied by analyzing their in 
vitro responses in the presence of either specific or irrelevant peptides. In 
chromium-51 release assay, each CTL line was able to recognize and kill 
only target cells pulsed with the specific peptide (30 to 80% lysis) but not 
the cells pulsed with irrelevant peptides (0 to 30% lysis) or unpulsed 
target cells (0 to 3% lysis). Picogram amounts of specific peptides were 
able to sensitize the target cell to CTL-mediated killing, indicating the 
high affinities of the isolated CTL lines. In addition to the cytotoxic 
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response, specific peptides induced significant proliferation of the CTL 
lines, proliferation indices ranging from 3 to 98.  Furthermore, a high 
amount of TNF-? (approximately 4 000 pg/ml) and IFN-? (approximately 
32 000 pg/ml) cytokines was produced by the CTL lines with the specific 
peptide stimulus (0.5-1 ?g), whereas no proliferation and cytokines was 
detected in the absence of the specific peptide. The CD8+ phenotype of 
long-term cytotoxic lines was confirmed by immunostaining and flow 
cytometric analysis; >95 % of cells being CD8+ cells. In addition, only 
neutralization of CD8+ T cells in vitro by antibodies, in contrast to CD4+ 
T cells, reduced the amount of cytolysis from 10 to 60%, suggesting that 
the cytotoxic activity was due to CD8+ T lymphocytes. 
To determine the biological relevance of the identified peptides, the 
ability of the CTL lines to respond to C. pneumoniae infected target cells 
in vitro was tested by measuring cytotoxic activity and cytokine 
production. Recognition and killing of infected cells would indicate that 
the identified peptides are natural epitopes, produced and presented 
through the natural class I processing pathway during C. pneumoniae
infection. Three out of seven CTL lines were activated in the presence of 
the target cells infected with C. pneumoniae.  The CTL line specific for 
Omp2-derived peptide 8282 showed both a moderate cytotoxic response 
(22% lysis) and TNF-? response (600 pg/ml) against infected target cells. 
CTL line 8511, specific for another Omp2-derived peptide, showed only 
increased cytotoxicity (20% lysis) but no cytokines in response to infected 
target cells, whereas the CTL line specific for MOMP-derived peptide 
7087 showed increased IFN-? production (1 600 pg/ml) but no cytotoxic 
response (8% lysis). On the basis of these data, altogether 19 
immunogenic peptides were identified from four C. pneumoniae proteins. 
Seven peptides induced long-term CTL lines, and three of these peptides 
(8482, 8511, and 7087) represent natural epitopes presented by the 
infected cell. 
Both cytotoxic activity and cytokine levels of the CTL lines in response to 
infected cells were much lower than those reached with the specific 
peptides. There are several possible explanations for this. First, this may 
be due to the relatively low infection frequency (50-70%) of target cells 
resulting in lower number of appropriate target cells after infection 
compared to the number of peptide-pulsed target cells. Second, the 
infected cells are likely to present multiple epitopes from bacterium, thus 
reducing the density of the specific peptide at the surface. Third, the 
antigens are differently expressed during C. pneumoniae infection, and 
may not be relevant for the infectious stage of the target cells used in 
assays. Fourth, since all chlamydial proteins may not enter the host 
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cytosol for antigen processing and presentation, it is possible that certain 
antigens do not provide epitopes that are recognized during C.
pneumoniae infection. Fifth possibility for failure of recognition might be 
due to impaired MHC I expression of infected cells. A eukaryotic protein 
inhibitor, cycloheximide, which is required for an efficient in vitro C.
pneumoniae infection of many murine cell lines, was used during 
infection assays, and even though the cycloheximide was washed away 
before the CTL assay, this may have resulted in lower MHC I expression. 
Furthermore, MHC class I downregulation has been observed during 
chlamydia infection. Chlamydial protease (CPAF) degrades host 
transcription factors, such as RFX5, required for MHC expression (Zhong 
et al., 2001). C. pneumoniae infection induces also strong IL-10 secretion 
which may downregulate the expression of MHC class I molecules in 
infected cells (Caspair-Bauguil et al., 2000).
5.1.3. The role of CD8 epitopes in protection against C. pneumoniae infection 
In order for an epitope restricted by class I MHC molecules to be 
protective, the responding T cells must be able to recognize and eliminate 
infected cells and prevent the infection in vivo. The protective role of 
identified natural epitopes was assessed by challenging mice with C. 
pneumoniae upon peptide immunization. Even though the subcutaneous 
immunizations with peptides 7087, 8282 and 8511 combined with helper 
epitopes and an adjuvant primed the peptide-specific CTL lines in vivo, 
the immunizations were not able to protect the mice from pulmonary 
infection. We demonstrated that T cells only from mice immunized with a 
peptide 8511 proliferated following stimulation with corresponding 
peptide in vitro indicating that the peptide-specific cell population had 
only a limited ability to expand to the infection site. A low number of 
peptide-specific effector cells in the lungs might at least partly explain the 
observed ineffectiveness of the subcutaneous peptide immunization 
against pulmonary infection. In addition, the peptide-specific CTL 
generated following peptide immunization can be fully functional but may 
be inefficient in clearing bacteria due to poor expression of parent 
antigens at the site of infection or interference of antigen presentation in 
vivo. A combination of different epitopes might expand the recognition of 
C. pneumoniae infected cells and induce more effective elimination of 
bacteria. Different administration routes, carrier systems and use of 
immunomodulators can be used to facilitate peptide delivery, maintain the 
integrity of peptides, and enhance the antigenicity and adjuvanticity of 
peptide vaccines.  
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5.2. HLA-A2.1 transgenic mouse (HHD) model  
HLA-A2.1 transgenic mice express classical human class I molecules 
thereby facilitating studies on immunisation strategies for effective 
prevention and treatment of human infectious diseases and cancer. Both
mouse and human cells are capable of processing same epitopes if they 
express same MHC class I molecules, indicating that the antigen 
processing machinery is a conserved system across species (Falk et al.,
1993). In addition, the overlap between T cell receptor specificities of 
mouse and human T cells enables the mouse CD8+ T cells to recognize 
specific peptides presented by human MHC class I molecules.   
HHD mice express a transgenic monochain class I molecule composed of 
human ?1 and ?2 domains of HLA-A2.1 covalently linked to human ?2-
microglobulin, and ?3 domain and cytoplasmic domain of mouse H-2Db
molecule (Pascolo et al., 1997) (Figure 4). The allele HLA-A2.1 is 
commonly chosen due to its high prevalence among the Caucasian 
population. Since mouse H-2Db and ?2-microglobulin genes are disrupted 
in HHD model, the only class I molecule expressed by the HHD mice is 
the HLA-A2.1/H-2Db hybrid transgene. The HHD strain provides a good 
model to evaluate the capacity of various immunogens to elicit CTL 
responses restricted by the HLA-A2.1 molecule. 
Figure 4. A schematic representation of the structure of the HLA-A2.1 
monochain composed of mouse (hatched area) and human (open area) 
domains covalently linked to human ?2-microglobulin (modified from 
Pascolo et al., 1997). 
mouse H-2Db α3
mouse transmembrane  
and cytoplasmic domains 
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5.2.1. Kinetics of C. pneumoniae infection in HHD mice 
The rather low expression of the transgenic HLA/Db monochain has been 
observed in HHD mice (Pascolo et al., 1997), and this may explain the 
low number of CD8+ T cells detected in HHD mice. Since the previous 
studies support the importance of CD8+ T cells in anti-C. pneumoniae
immunity (Penttilä et al., 1999), it was essential to test first whether this 
HHD model is suitable for studying C. pneumoniae infection in vivo. 
Following the intranasal challenge of 105 IFU, the HHD mice developed a 
pulmonary infection that peaked at approximately 105 IFU/lung during the 
first three weeks after which the number of bacteria in the lungs gradually 
declined and by day 49, all mice were typically culture negative. 
Rechallenge of the culture negative, but already once infected HHD mice 
led to a faster and more efficient clearance of reinfection shown by a 
lower number of culturable bacteria for a shorter time in lungs compared 
to the primary infection (Figure 5). The number of bacteria cultured from 
wild type C57BL/6 mice was approximately 10-100 -fold lower than that 
of HHD mice after the challenge but the overall infection kinetics and the 
time needed for clearance were similar in the mouse strains.  
Figure 5. Culture results (medians and upper and lower quartiles) from the 
HHD lung samples at indicated time points after the primary challenge 
(columns) and rechallenge (line). * = statistically significant difference 
between primary challenge and rechallenge (p< 0.05) as determined by 
Mann-Whitney U-test. Arrow shows the detection limit of 10 IFU / lung. 
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Our results showed that the transgenic HHD mice were able to restrict C. 
pneumoniae infection and develop protective immune responses against 
subsequent infection. In addition, the clearance of C. pneumoniae
infection and a partial protection seem to be independent of nonclassical 
MHC I molecules. Besides the classical MHC I molecules, HHD mice are 
unable to express nonclassical MHC I molecules containing ?2-
microglobulin chain (CD1/H2-M3) because of the disrupted murine ?2m
gene. The initially lower numbers of CD8+ T cells in HHD mice could 
have hindered activation of protective immune responses and resulted in 
higher numbers of culturable bacteria than detected in the wild type mice.  
5.2.2. Immune responses during C. pneumoniae infection in HHD 
mice
The proportions of different lymphocyte subsets in HHD mice were 
assessed by staining for cell surface markers. Overall, the proportion of 
CD8+ T cells in HHD mice was constantly lower in all tissues as 
compared to wild type C57BL/6 mice. The proportion of CD4+ T cells in 
the HHD mice was equal or slightly higher when compared to the wild 
type mice. However, after infection the number of mononuclear cells in 
the lungs increased approximately 10-fold as compared to uninfected 
mice, indicating an accumulation of lymphoid cells to the lungs of HHD 
mice upon infection. The proportion of CD8+ T cells increased 
approximately 5-fold during primary infection and 3-fold during 
reinfection (Figure 6), whereas the proportions of CD4+ T cells and 
CD19+ B cells did not clearly increase upon challenge.
To characterize the HHD-derived cell populations after C. pneumoniae 
infection, the cells were isolated from the lungs and spleen. The cells 
were stimulated in vitro with UV-inactivated C. pneumoniae EB, and 
their capacity to proliferate and secrete cytokines was assessed. HHD-
derived cells isolated after C. pneumoniae infection responded to UV-
inactivated EB stimulus by as strong proliferation as did the cells from 
infected wild type mice. However, IFN-? production was clearly lower in 
the cells isolated from infected HHD mice compared to the cells isolated 
from infected wild type mice. Together with the observation that lower 
numbers of CD8+ T cells occur in HHD spleen, we concluded that C. 
pneumoniae-induced IFN-? production was at least partly a CD8-
dependent and HLA-A2.1-restricted function. 
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Figure 6. Accumulation of CD8+ T lymphocytes in the lungs of HHD 
mice during primary infection and reinfection. 
The importance of CD8+ cells in C. pneumoniae infection in HHD mice 
was further assessed using in vivo depletion of CD8+ cells during 
reinfection. The first dose of CD8-specific antibody (clone YTS 169) was 
injected intraperitoneally one day before the reinfection and every third-
fourth day thereafter. A control group was treated with purified IgG from 
pooled normal rat serum. The efficacy of depletion was 83% and 96% in 
HHD and C57BL/6 mice, respectively. The depletion of CD8+ cells 
during reinfection impaired clearance of infection in both mouse strains as 
measured on day 12 after rechallenge (Figure 7). Although the difference 
did not reach statistical significance in either of the mouse strains it 
suggests higher susceptibility of CD8-depleted mice to reinfection. The 
proliferative capacity of HHD splenocytes isolated after CD8 depletion 
(proliferation index of 2.3) was slightly weaker compared to splenocytes 
isolated from control mice (proliferation index of 3.4). In addition, CD8-
depleted HHD cells produced lower levels of IFN-γ (below detection limit 
20 pg/ml) than those from control HHD mice (75 pg/ml) indicating that 
the production of chlamydia-specific IFN-γ is at least partly CD8+ T cell-
dependent.
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Figure 7. Pulmonary bacterial loads of infected HHD mice (dark 
columns) and C57BL/6 mice (white columns) with or without CD8-
depletion. Culture assay was performed at day 12 after rechallenge 
(infectious dose was 105 IFU/mouse). Arrow shows the detection limit of 
10 IFU / lung. 
5.2.3. Identification of HLA-A2.1-restricted CD8 epitope
To study the antigen processing and presentation pathways and the 
induction of CTL response in HHD mice, we immunized the HHD mice 
with recombinant chlamydial outer protein N (CopN), and isolated the 
CTL lines against CopN-derived peptides. Eight peptide sequences 
possessing HLA-A2.1 binding residues were synthesized as potential CD8 
epitopes, and their binding capacity to HLA-A2.1 molecule was tested in 
MHC I stabilization assay (Table 5). After the HHD mice were 
immunized with heat-aggregated CopN protein, the splenocytes were 
isolated and stimulated with each of these peptides in vitro. After two 
weeks of restimulation, a CTL line specific for peptide 1227 
(ILALVQEKI) was detected in cell cultures isolated from CopN-
immunized HHD mice. In contrast, no CTL lines could be isolated from 
unimmunized mice after stimulation with peptides. 
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Table 5. CopN-derived HLA-A2.1 –restricted peptides. The peptide 
which stimulated a strong CTL-response is in bold. 
The CTL line specific for peptide 1227 was able to recognize and kill 
only a target cell coated with the specific peptide 1227 (50-70% lysis), but 
it did not respond to a target cell coated with other, irrelevant peptides 
(<5% lysis) or a target cell without peptide (<5% lysis), indicating a 
specificity of the CTL line for a certain peptide.  In addition to the 
cytotoxic activity, the peptide 1227-specific CTL line proliferated and 
produced IFN-? following specific peptide stimulation. These results 
indicate firstly that the HLA-A2.1 transgenic mice were able to process 
and present chlamydial antigen as a part of HLA-A2.1 complex and 
secondly that the mouse CD8+ cells were able to recognize C.
pneumoniae antigen in an HLA-A2.1-restricted manner. On the basis of 
this data, we conclude that the HHD mouse model can be used for the 
identification of human CD8 epitopes from chlamydial antigens.  
To test whether this human CD8 epitope 1227 is also processed and 
presented by C. pneumoniae infected cells, we analyzed the cytotoxic and 
cytokine responses of CTL line 1227 against C. pneumoniae infected 
target cells. Very low but detectable cytotoxicity and IFN-? response was 
measured against in vitro infected macrophages isolated from HHD mice. 
Only a faint response may indicate that this CTL line is not significant in 
protection. On the other hand, the lack of cytotoxicity may not be due to a 
defect in the CD8+ T cell, but rather a defect in the target cell itself. The 
density of the CopN-derived epitope 1227 may be so low at the surface of 
an infected cell that the CTL line is not able to become active. Reverse 
Protein Peptide name Sequence and position Prediction score Experimental binding 
to  HLA-A2.1 
CopN 1223 332 LIGDDVDSV 340 27 + 
 1224 202 GLRSLYLEV 210 25 - 
 1225 140 ALQSTALDYL 149 27 - 
 1226 171 MIANALDAV 179 25 ++ 
1227 128 ILALVQEKI 136 24 + 
 1228 262 VLMTETRNL 270 24 + 
 1229 343 VLNLFFSAL 351 24 - 
 1230 9 GLGGTQGVNL 18 25 - 
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transcriptase PCR studies have shown that the transcription of CopN is 
temporally regulated during C. pneumoniae infection and only detected at 
later stages of the developmental cycle (Slepenkin et al., 2003). In 
addition, macrophages may restrict the C. pneumoniae infection so that 
the expression of CopN is limited (Haranaga et al., 2003). Therefore, the 
role of this epitope in protection against C. pneumoniae infection in vivo 
remains to be studied.  
5.3. CTL response induced by DNA immunization 
Within the same antigen different epitopes can be processed with variable 
efficiencies. DNA vaccines encoding chosen proteins provide tools for 
studying endogenously processed antigens and the spectrum of the 
induced CTL response. By largely unknown mechanisms the naked DNA 
is taken up into the host cells, followed by generation of proteins that 
enter the MHC class I pathway and induce the CD8+ T cell response. 
Immunization of BALB/c mice with DNA encoding chlamydial Omp2 
protein (Penttilä et al., 2000) induced a CTL response against peptide 
8511, one of the identified natural epitopes. Similarly, DNA encoding 
chlamydial MOMP protein induced a CTL response against peptide 7205 
which is the peptide also capable of inducing CTL response after peptide 
immunization (Table 4). According to a study of Vitiello et al., peptides 
8511 and 7205 may be categorized to immunodominant epitopes because 
both the peptides and the DNA encoding the corresponding antigen were 
able to induce the CTL response (Vitiello et al., 1997). By contrast, CTL 
response against peptide 8482 was detected only after peptide 
immunization, and the peptide-specific CTL line was able to recognize 
the infected target cells. These findings suggest that the peptide 8482 may 
be a subdominant epitope presented by infected cells or DNA-immunized 
cells at a density that is sufficient to induce target cell killing but 
insufficient to prime CTL response. Since a CTL response can be primed 
against these subdominant epitopes by using peptide immunization, they 
may have therapeutic potential. A third category contains cryptic epitopes 
that induce CTL response only after peptide immunization and the lines 
can recognize only peptide-coated target cells (Vitiello et al., 1997). At 
least two explanations for crypticity can be presented. One reason could 
be that the epitope is not generated in the course of antigen processing, 
and another is that the epitope is recognized only by low-avidity T cells 
which are incapable of responding to targets presenting a specific epitope 
at low density. However, by introducing point mutations to epitopes that 
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improve their interaction with MHC class I molecules CTL response has 
been elicited even against cryptic epitopes (Tine et al., 2005). 
In addition to priming the CTL response, immunization with DNA 
encoding chlamydial MOMP has been shown to result in 1.2-1.5 log 
reduction in the lung bacterial counts (Penttilä et al., 2000). Although the 
immunization with DNA/Omp2 induced an antigen-specific immune 
response including a strong systemic antibody response against Omp2 
protein, it did not protect the mice from C. pneumoniae challenge. 
5.4. Semliki forest virus (SFV) immunization 
To optimize the effect of chlamydial protein-based DNA immunization 
we tested Semliki Forest virus (SFV) as a delivery vector (Liljeström et
al., 1991). This single-stranded RNA alphavirus which drives its own 
replication has shown clinical efficacy and safety in various in vitro and 
in vivo applications (reviewed by Tubulekas et al., 1997). This is 
principally because of its capacity to express large amounts of 
heterologous protein, and its broad host range. In addition, RNA 
replication is cytoplasmic and there is no risk for chromosomal 
integration. Since most humans and animals do not naturally come into 
contact with SFV, preexisting immunity does not decrease the efficacy. 
SFV vectors have a relatively large cloning capacity and the constructs are 
relatively easily and quickly engineered.
In the previous project, chlamydial genes encoding MOMP and Omp2 
(ompA and omcB, respectively) were cloned into pcDNA3.1 eukaryotic 
expression vector and used as DNA vaccines (Penttilä et al., 2000). In this 
study, the same sequences were cloned into the SFV4.2 vectors to 
compare the different delivery vehicles and their efficacy. The 
recombinant SFV (rSFV) particles were prepared by co-transfection of 
BHK-21 cells with in vitro transcribed RNA coding for the desired 
chlamydial gene and a packaging signal, and two helper-constructs coding 
the viral structural proteins. This resulted in the packaging of recombinant 
RNA into virions and their subsequent release from the cell. The rSFV 
particles expressing ?-galactosidase were used as control. Since the viral 
structural genes were deleted in the vector and supplied only by the 
helpers, new viruses cannot be assembled in the immunized mice. The 
expression of chlamydial proteins was confirmed by infecting BHK-21 
cells with rSFV constructs and analyzing the newly synthesized proteins 
by metabolic labeling and autoradiography. A moderate expression level 
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of chlamydial recombinant proteins was detected on SDS-PAGE 
compared to the strong expression of control protein ?-galactosidase.
To monitor the influence of two different immunization strategies, the 
BALB/c mice were either immunized twice with rSFV or first primed 
twice with naked DNA followed by boosting with rSFV. Induced humoral 
immune response was analyzed by measuring the systemic antibody 
response against recombinant MOMP and Omp2 proteins. Immunization 
with Omp2 constructs by both methods induced a significant Omp2-
specific antibody production: log10 titer 2.5 after rSFV immunization and 
log10 titer >3.7 after DNA/rSFV immunization. In addition, DNA 
combined with rSFV induced both IgG1 (titer 3.3) and IgG2 (titer 2.8) 
antibodies against Omp2, whereas the immunization with viral particles 
induced only Omp2-specific IgG1 antibodies (titer 1.7). An induction of 
strong serum IgG2a antibody response suggests that DNA combined with 
SFV induces more Th1 type biased immunity. On the contrary, no 
antibodies against MOMP antigen were detected after immunization with 
MOMP constructs consistent with the findings observed after vaccination 
with naked DNA (Penttilä et al., 2000). Poor antibody production may be 
due to suboptimal expression of C. pneumoniae MOMP in mammalian 
cells or retention and degradation of misfolded protein inside the cell. 
Mice immunized with control constructs (vector expressing ?-
galactosidase or empty vectors) did not produce antibodies against 
MOMP and Omp2 antigens. 
To determine the cellular responses after different immunization 
protocols, the splenocytes were isolated and stimulated in vitro with 
inactivated whole C. pneumoniae bacteria or purified recombinant 
proteins (MOMP, Omp2). Proliferative activity of the splenocytes and 
secretion of IFN-? were measured after in vitro stimulation. Priming and 
boosting the mice with the viral vector induced a high background 
proliferation of isolated splenocytes that masked the possible antigen-
specific response. However, both MOMP and Omp2-specific IFN-?
production (300-5000 pg/ml) of isolated splenocytes was detectable after 
corresponding rSFV immunization. In addition, C. pneumoniae-specific 
IFN-? production was approximately 2-fold higher in mice immunized 
with rSFV/MOMP (1600 pg/ml) or rSFV/Omp2 (1200 pg/ml) than in 
control mice immunized with rSFV/?gal (800 pg/ml). Priming with DNA 
and boosting with rSFV induced both antigen-specific proliferation of 
isolated splenocytes and antigen-specific IFN-? production (100-200 
pg/ml) but the responses were lower than after two injections of rSFV. 
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5.4.1. CTL response induced by SFV immunization 
The induction of CTL response by rSFV immunizations was studied by 
isolating peptide-specific CTL lines from the spleen of the immunized 
BALB/c mice. After the rSFV immunization, splenocytes were stimulated 
in vitro with the different mixtures of MOMP- or Omp2-derived synthetic 
peptides possessing H-2d-binding residues (Table 4). As a positive 
control, a previously described epitope 9339 of E. coli ?-galactosidase 
was used to stimulate the splenocytes from the control mice immunized 
with rSFV/?-galactosidase (Gavin et al., 1993). As a negative control, the 
MOMP- and Omp2-derived peptide mixtures were used to stimulate the 
splenocytes from the control mice immunized with rSFV/?-galactosidase. 
Three long-term peptide-specific CTL lines were isolated after the rSFV 
immunization and in vitro stimulation: a CTL line from rSFV/?gal
immunized mice recognizing peptide 9339 (a positive control), a CTL line 
from rSFV/MOMP immunized mice recognizing peptide 7205 
(RGNSTAFNL) and a CTL line from rSFV/Omp2 immunized mice 
recognizing peptide 8511 (CYGRLYSVKV). Most interestingly, these 
two chlamydial peptides 7205 and 8511 identified after the Semliki Forest 
virus immunization were exactly the same peptides than those identified 
after the immunization with naked DNA. These findings indicate that both 
antigen delivery vehicles (rSFV and naked DNA) direct the encoded 
MOMP and Omp2 proteins similarly to the endogenous antigen 
processing pathway and provide presentation of the same chlamydial 
epitopes.
To assess the induction of protective immunity, the immunized mice were 
challenged with C. pneumoniae and the bacterial counts in the lungs were 
compared between the immunized groups. In agreement with previous 
DNA vaccination studies (Penttilä et al., 2000), rSFV constructs encoding 
chlamydial MOMP or Omp2 proteins were able to induce antigen-specific 
Th1 type immune response including the CTL response, but only partial 
protection against C. pneumoniae infection. In addition, the prime-boost 
technique involving heterologous vectors (DNA and rSFV) coding for the 
same antigen was not sufficient for enhancing the immunity obtained by 
immunization with DNA or rSFV vaccines alone. However, both 
immunization protocols (rSFV and DNA/rSFV) reduced the numbers of 
bacteria in mice immunized with MOMP or Omp2 constructs compared 
to the control mice immunized with control vectors. Mice immunized 
with rSFV/MOMP and DNA/rSFV/Omp2 had a statistically significant 
decrease in the lung bacterial load compared to the controls. Since the 
efficacy of vaccines based upon MOMP or Omp2 proteins has been 
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limited, novel chlamydial antigens or a mixture of different antigens may 
be required for an optimal vaccine. However, immunizations with genetic 
constructs provide an efficient method for screening potential new 
antigens and their protective action.
5.5. Immunization with heat-aggregated chlamydial outer protein N 
(CopN)
Compared with other delivery vehicles, such as DNA and rSFV carrying 
the genes of interest, use of heat-treated antigen preparations may offer an 
even more simple way to deliver antigen into the class I pathway and 
obtain a CTL response. Since exogenous proteins are mainly processed 
via the endosomal MHC class II pathway, they are rather inefficient in 
priming CTL response. Denaturation of the protein antigen by heat has 
been shown to enhance the immunogenicity of exogenous antigens, 
probably because of easier access to the MHC class I loading pathway 
(Speidel et al., 1997). The purpose of this study was to determine the 
capability of heat-treated chlamydial outer protein (CopN) to induce 
immune responses against C. pneumoniae infection. CopN is a chlamydial 
protein supposed to be secreted into the inclusion membrane by TTSS 
(Fields et al., 2000; Lugert et al., 2004). Secreted chlamydial proteins are 
potential targets for the host cell antigen processing and presentation 
pathways, thereby representing attractive antigen candidates for T cell-
based vaccination. Recombinant CopN protein was readily expressed in a 
Bacillus system (Airaksinen et al., 2003) as a soluble protein. Intranasal 
immunization of BALB/c mice with the recombinant CopN proteins 
combined with E. coli heat-labile toxin (LT) induced a strong antigen-
specific immune response. Both untreated CopN and heat-treated CopN 
induced significant CopN-specific antibody production (Ig titers >4.0) 
whereas no antibodies against purified C. pneumoniae EB (Ig titers <2.0) 
were detected in EIA analysis. This observation means that either the 
CopN is not exposed at the surface of purified C. pneumoniae EB or the 
antibodies induced by recombinant CopN can not recognize the 
conformational CopN epitopes on the surface of the bacterium. Our 
finding, that these CopN-specific antibodies are, however, able to 
recognize and bind to the intracellular inclusions during chlamydial 
growth, supports the former rather than the latter presumption.  
To study the cellular responses induced by CopN immunization, 
mononuclear cells were isolated from immunized mice and stimulated 
with the CopN protein and UV-inactivated C. pneumoniae EB in vitro. 
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After CopN immunization, enlargement of mediastinal lymph nodes 
(mLN) was observed, which is usually detected only after C. pneumoniae
challenge. The cells isolated from mLN, lung, blood and spleen after the 
CopN immunization proliferated strongly when stimulated with the CopN 
protein in vitro (proliferation indices (PI) of 11, 15, 5 and 16, 
respectively). The cells isolated from the control mice immunized with 
PBS and LT did not respond in vitro to CopN (spleen-derived 
proliferation index of 0). Proliferative response against UV-inactivated C.
pneumoniae was slightly higher in the CopN/LT-immunized group (e.g. 
PI of splenocytes range of 3-6) compared to PBS/LT-immunized control 
mice (PI splenocytes range of 0.2-3). In addition, the splenocytes of CopN 
immunized mice showed a moderate IFN-? response after in vitro 
stimulation with CopN protein (120 pg/ml) as compared to splenocytes 
isolated from the control mice (below detection limit 20 pg/ml). These 
results indicate that the intranasal immunization with heat-aggregated 
chlamydial protein and LT adjuvant induces a strong humoral and cellular 
Th1 type response, detected not only at the site of immunization and 
infection (lung) and draining lymph nodes (mLN) but also in circulation 
(blood) and in the peripheral lymphoid organ (spleen).  
Most interestingly, after the immunization with heat-aggregated CopN 
and LT adjuvant, a significant level of protection against C. pneumoniae
infection was observed at day 14 after the challenge. CopN immunization 
completely protected 5 out of 10 mice and reduced clearly the bacterial 
titers of the five positive animals (300 -1000 IFU/lung). In contrast, 900-
6000 IFU could be cultured from infected control mice immunized with 
Mock (disrupted HL cell debris) (Figure 8A). All challenged mice 
developed an IgG antibody response against C. pneumoniae confirming 
that all mice had been successfully challenged. The observed intragroup 
variation in protection may be due to unequal protein amounts in samples 
that were injected into the mice during the immunization. Boiling of the 
protein samples precipitates the protein, and unseparated suspensions of 
heat-denatured proteins seem to be less efficient in immunization than the 
pelleted heat-denatured sample (Speidel et al., 1997). Correspondingly, an 
equal amount of native CopN without heat-treatment induced protection 
to a lesser degree (median IFU per lung (log) 2.5) compared to that 
induced by heat-aggregated CopN (median IFU per lung (log) 1.5). 
Comparison of the immune responses of individual mice and the 
protection level revealed that the CopN-specific proliferative response of 
mLN was negatively correlated with the number of IFU recovered from 
lungs (rho = -0.77). The protection was strongest in the mice with the 
highest antigen-specific proliferation activity in mLN. This may indicate 
that the immunization of some mice was more efficient resulting in a 
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stronger antigen-specific response and protection against C. pneumoniae
infection. Responses to UV-inactivated C. pneumoniae were, however, 
surprisingly similar in CopN and PBS immunized groups and did not 
correlate with protection. Maybe the UV-inactivated particles are unable 
to induce CopN-specific immune responses in the in vitro assays.
Corresponding CopN-immunization assay was also performed in HLA-
A2.1 transgenic HHD mice, and a similar trend was observed; HHD mice 
showed a clearly decreased number of IFU /lung after immunization with 
CopN compared to HHD mice immunized with Mock (Figure 8B). 
Figure 8. The protective effect of CopN immunization against C. 
pneumoniae challenge. BALB/c (A) and HHD (B) mice were immunized 
either with heat-aggregated disrupted HL cells (Mock) or heat-aggregated 
CopN protein together with LT adjuvant. Two weeks after the last 
immunization mice were challenged intranasally with 105 IFU of C.
pneumoniae. Fourteen days after the challenge, the mice were sacrificed 
and bacterial load was assessed from homogenized lung supernatants. 
Culture results of individual mice (black diamonds) and medians (lines) 
of logarithmic values are shown. Arrows show the detection limit, 10 
IFU/lung.
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Most antigens are unable to induce immune responses when administrated 
alone via a mucosal route, and special care must be taken to achieve the 
optimal immune response and to avoid mucosally induced tolerance. The 
importance of an adjuvant is to favor the generation of a protective type of 
immune response against a coadministered antigen. To assess the 
influence of LT adjuvant, the mice were immunized with heat-aggregated 
CopN with or without LT adjuvant followed by challenge with C. 
pneumoniae. Without LT adjuvant, CopN, even after heating was rather 
ineffective, and the bacterial load (median IFU per lung (log) 3.4), was 
almost as high as in the control mice immunized with PBS and LT 
(median IFU per lung (log) 3.6). This finding suggests that the 
simultaneous intranasal delivery of LT adjuvant and CopN antigen can 
remarkably enhance the protective immune responses against pulmonary 
C. pneumoniae infection. E. coli heat-labile enterotoxin, LT is a powerful 
mucosal adjuvant potentiating both systemic and local immune responses 
including CTL response to a coadministered antigen (Simmons et al.,
1999). LT and its nontoxic derivatives LTK63 and LTR72 have been 
extensively exploited as mucosal adjuvants in animal models (Pizza et al., 
2001). In addition to adjuvant capacity, bacterial AB5 toxins and their 
subunits have been used as vehicles for efficient delivery of antigens into 
the class I pathway (Smith et al., 2002; de Haan et al., 2002). Although 
the adjuvant capacity of these toxins is not linked to their ability to deliver 
antigens (Williams et al., 1999), it is expected that toxins that combine 
these two properties will be most suitable for immunotherapy. 
Interestingly, a recent study shows that the administration of LTK63, a 
nontoxic derivative of LT, prevents the immunopathology associated with 
infections due to a number of respiratory pathogens (Williams et al.,
2004).
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6. CONCLUSIONS AND FUTURE PROSPECTS 
The optimal generation of a cytotoxic CD8+ T cell (CTL) response 
continues to be a challenge in the production of vaccines against 
intracellular pathogens, in part because it is relatively difficult to 
introduce antigens into the MHC class I pathway. This study involved the 
generation and characterization of CTL response in an experimental 
mouse model used for studying C. pneumoniae infection.
The first approach to stimulate CTL response was based on the 
identification of peptides from C. pneumoniae proteins expected to bind 
to the MHC class I molecules on the surface of APC. Several CD8 T cell 
epitopes were identified from the amino acid sequence of four C.
pneumoniae proteins (MOMP, Omp2, Hsp60, and Pomp5) using the 
computer based algorithms (Rammensee et al., 1999) and peptide 
immunization. Here, we proved the efficacy of this model in the 
identification of chlamydia-derived CD8 epitopes that are able to induce 
CTL immunity in vivo. Furthermore, with the help of HLA-transgenic 
mice we identified a C. pneumoniae-derived peptide which is presented 
by a classical human class I molecule (HLA-A2.1). HLA-transgenic mice 
provide a humanized mouse model for monitoring HLA-restricted CTL 
responses against C. pneumoniae infection.
The identification of the CD8 epitopes is essential in order to detect the 
specific CD8+ T cell response, and to evaluate the function and 
phenotype of individual T cells during infection or after immunization. In 
contrast to the indirect assays, intracellular cytokine staining, the enzyme-
linked immunosorbent spot assay (ELISPOT), and the fluorescent MHC I 
tetramers loaded with peptides allow direct monitoring of very low 
numbers of peptide-specific T cells without the need for in vitro
expansion. These novel methods are able to track antigen-specific CTL 
with greater specificity and sensitivity but require previous identification 
of the epitopes. Identified CD8 epitopes also permits the development of 
specific preventive and therapeutic approaches in infectious diseases. 
Subcutaneous immunizations with the single epitopes identified in this 
study induced splenic CTL responses but were unable to protect the mice 
from pulmonary C. pneumoniae challenge. There may be a certain 
threshold of effector CD8+ T cells that is required for the protection 
against challenge. Polyepitope constructs would elicit the CTL response 
against multiple antigens, and induce a broader and more potent immune 
response. A recent report demonstrated that a DNA minigene vaccine 
encoding seven CTL epitopes from seven C. pneumoniae antigens, the 
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universal Th epitope and ER-translocating signal sequence, induced 
significant protection against intranasal C. pneumoniae challenge in mice 
(Pinchuck et al., 2005). Currently, the combination of an epitope 
prediction program with an overlapping peptide library seems to be the 
most comprehensive and effective method for the identification of CD8
epitopes within an antigen; larger antigenic fragments (longer peptides or 
DNA fragments) enable the CD8+ T cell epitopes to be rapidly identified 
without preparing numerous synthetic peptides (Suzuki et al., 2004; Aoshi 
et al., 2005).
The second approach to stimulate CTL response was based on the 
synthesis of an antigen by the APC and exploiting the classical cytosolic 
MHC I pathway. DNA- and RNA-based vaccines, as well as viral vectors, 
deliver the nucleic acids into the cytoplasm of APC for antigen 
processing. Immunization with both DNA and rSFV encoding chlamydial 
antigens mobilized a wide range of effector mechanisms, and the results 
speak in favor of using genetic constructs for the further evaluation of 
vaccine antigens and protective immune responses against C. pneumoniae 
infection.
Chlamydial proteins which have access to the host cell cytosol are likely 
to be present to the CD8+ T cell, which makes them of particular interest 
for vaccine development. Heat-aggregated recombinant CopN protein, a 
substrate of type III secretion system of chlamydia, induced a statistically 
significant, in some mice even sterilizing immunity against C.
pneumoniae infection, a result much better than that obtained with natural 
infection. This certainly recommends this antigen as a candidate vaccine 
for further investigation. Since the natural C. pneumoniae infection 
induces only partial protection against the repeated reinfections, 
sterilizing protection requires the development of a vaccine that is better 
than the natural antigens in inducing immunity. 
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